WO2021151030A1 - Automated analyte measurement systems and kits for use therewith - Google Patents
Automated analyte measurement systems and kits for use therewith Download PDFInfo
- Publication number
- WO2021151030A1 WO2021151030A1 PCT/US2021/014800 US2021014800W WO2021151030A1 WO 2021151030 A1 WO2021151030 A1 WO 2021151030A1 US 2021014800 W US2021014800 W US 2021014800W WO 2021151030 A1 WO2021151030 A1 WO 2021151030A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- electrode
- wells
- automated
- assay
- agents
- Prior art date
Links
- 239000012491 analyte Substances 0.000 title description 97
- 238000005259 measurement Methods 0.000 title description 19
- 239000007788 liquid Substances 0.000 claims abstract description 154
- 238000003556 assay Methods 0.000 claims abstract description 146
- 238000000034 method Methods 0.000 claims abstract description 41
- 239000012530 fluid Substances 0.000 claims description 32
- 230000007246 mechanism Effects 0.000 claims description 11
- 238000012545 processing Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 148
- 238000011002 quantification Methods 0.000 abstract description 115
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 54
- 239000000872 buffer Substances 0.000 abstract description 13
- 239000000523 sample Substances 0.000 description 118
- 239000003795 chemical substances by application Substances 0.000 description 35
- 239000000090 biomarker Substances 0.000 description 33
- 108090000623 proteins and genes Proteins 0.000 description 28
- 102000004169 proteins and genes Human genes 0.000 description 28
- 108091006146 Channels Proteins 0.000 description 22
- 238000010586 diagram Methods 0.000 description 21
- 238000005070 sampling Methods 0.000 description 21
- 238000003018 immunoassay Methods 0.000 description 20
- -1 antibodies Proteins 0.000 description 19
- 239000000126 substance Substances 0.000 description 19
- 239000013543 active substance Substances 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 150000001720 carbohydrates Chemical class 0.000 description 17
- 235000014633 carbohydrates Nutrition 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 239000005556 hormone Substances 0.000 description 17
- 229940088597 hormone Drugs 0.000 description 17
- 150000002632 lipids Chemical class 0.000 description 17
- 229920002521 macromolecule Polymers 0.000 description 17
- 239000002207 metabolite Substances 0.000 description 17
- 238000003384 imaging method Methods 0.000 description 16
- 102000039446 nucleic acids Human genes 0.000 description 16
- 108020004707 nucleic acids Proteins 0.000 description 16
- 150000007523 nucleic acids Chemical class 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 238000010191 image analysis Methods 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 239000000427 antigen Substances 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 230000005611 electricity Effects 0.000 description 12
- 238000011330 nucleic acid test Methods 0.000 description 12
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 12
- 239000012472 biological sample Substances 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- 239000012898 sample dilution Substances 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 208000006265 Renal cell carcinoma Diseases 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000007405 data analysis Methods 0.000 description 9
- 230000005684 electric field Effects 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 230000002285 radioactive effect Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000002246 antineoplastic agent Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 7
- 230000033228 biological regulation Effects 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- 230000005284 excitation Effects 0.000 description 7
- 238000007901 in situ hybridization Methods 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 238000012775 microarray technology Methods 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 239000000419 plant extract Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000013535 sea water Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 229910052697 platinum Inorganic materials 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 108700011259 MicroRNAs Proteins 0.000 description 5
- 206010038389 Renal cancer Diseases 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002679 microRNA Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000012549 training Methods 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 4
- 239000000611 antibody drug conjugate Substances 0.000 description 4
- 229940049595 antibody-drug conjugate Drugs 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000001499 laser induced fluorescence spectroscopy Methods 0.000 description 4
- 201000010174 renal carcinoma Diseases 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 239000002249 anxiolytic agent Substances 0.000 description 3
- 230000000712 assembly Effects 0.000 description 3
- 238000000429 assembly Methods 0.000 description 3
- 239000006177 biological buffer Substances 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102100020880 Kit ligand Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108010039445 Stem Cell Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000038016 acute inflammation Diseases 0.000 description 2
- 230000006022 acute inflammation Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001780 adrenocortical effect Effects 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229940124325 anabolic agent Drugs 0.000 description 2
- 239000003263 anabolic agent Substances 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000004004 anti-anginal agent Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 229940124345 antianginal agent Drugs 0.000 description 2
- 239000003416 antiarrhythmic agent Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000000030 antiglaucoma agent Substances 0.000 description 2
- 229940030225 antihemorrhagics Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000003904 antiprotozoal agent Substances 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 229940124575 antispasmodic agent Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- IBIKHMZPHNKTHM-RDTXWAMCSA-N merck compound 25 Chemical compound C1C[C@@H](C(O)=O)[C@H](O)CN1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C1CC1 IBIKHMZPHNKTHM-RDTXWAMCSA-N 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000001617 Interferon Receptors Human genes 0.000 description 1
- 108010054267 Interferon Receptors Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 201000010829 Spina bifida Diseases 0.000 description 1
- 208000006097 Spinal Dysraphism Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 229940116731 Uricosuric agent Drugs 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002598 adenosine A1 receptor antagonist Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000000464 adrenergic agent Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000003081 alcohol deterrent Substances 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 201000006288 alpha thalassemia Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 230000001539 anorectic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000002272 anti-calculus Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 230000003374 anti-dyskinetic effect Effects 0.000 description 1
- 230000000603 anti-haemophilic effect Effects 0.000 description 1
- 230000002959 anti-hypotensive effect Effects 0.000 description 1
- 230000002553 anti-keratinizing effect Effects 0.000 description 1
- 230000002377 anti-obsessional effect Effects 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000001826 anti-prostatic effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000002682 anti-psoriatic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940124343 antiamebic agent Drugs 0.000 description 1
- 239000000059 antiamebic agent Substances 0.000 description 1
- 229940124344 antianaemic agent Drugs 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000003173 antianemic agent Substances 0.000 description 1
- 229940124346 antiarthritic agent Drugs 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 229940124538 antidiuretic agent Drugs 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940075522 antidotes Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000000504 antifibrinolytic agent Substances 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 229940082988 antihypertensives serotonin antagonists Drugs 0.000 description 1
- 229940124572 antihypotensive agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 239000002579 antinauseant Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000003200 antithyroid agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229940125690 blood glucose regulator Drugs 0.000 description 1
- 239000002617 bone density conservation agent Substances 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 229940045200 cardioprotective agent Drugs 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical class OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 1
- 239000000731 choleretic agent Substances 0.000 description 1
- 239000000064 cholinergic agonist Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 206010009259 cleft lip Diseases 0.000 description 1
- 239000002817 coal dust Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 239000003224 coccidiostatic agent Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940037530 cough and cold preparations Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 239000003975 dentin desensitizing agent Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 229940005501 dopaminergic agent Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 244000078703 ectoparasite Species 0.000 description 1
- 239000013057 ectoparasiticide Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 229940124563 hair growth stimulant Drugs 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 102000055222 human IL1B Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000005554 hypnotics and sedatives Substances 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940124452 immunizing agent Drugs 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000036997 mental performance Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000002637 mydriatic agent Substances 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 239000000133 nasal decongestant Substances 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 239000000842 neuromuscular blocking agent Substances 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002863 oxytocic agent Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000002445 parasympatholytic effect Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000004240 prostatic hypertrophy Diseases 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 201000003233 renal Wilms' tumor Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 239000003198 schistosomicide agent Substances 0.000 description 1
- 239000003229 sclerosing agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229940121356 serotonin receptor antagonist Drugs 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 239000003749 thyromimetic agent Substances 0.000 description 1
- 239000007852 tooth bleaching agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229940062627 tribasic potassium phosphate Drugs 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 230000000990 untiurolithic effect Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000003383 uricosuric agent Substances 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L9/00—Supporting devices; Holding devices
- B01L9/52—Supports specially adapted for flat sample carriers, e.g. for plates, slides, chips
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/10—Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/02—Burettes; Pipettes
- B01L3/0275—Interchangeable or disposable dispensing tips
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
- B01L3/5085—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above for multiple samples, e.g. microtitration plates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/0099—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor comprising robots or similar manipulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/10—Devices for transferring samples or any liquids to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
- G01N35/1065—Multiple transfer devices
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/02—Adapting objects or devices to another
- B01L2200/025—Align devices or objects to ensure defined positions relative to each other
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/04—Closures and closing means
- B01L2300/041—Connecting closures to device or container
- B01L2300/042—Caps; Plugs
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/04—Closures and closing means
- B01L2300/041—Connecting closures to device or container
- B01L2300/043—Hinged closures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0627—Sensor or part of a sensor is integrated
- B01L2300/0645—Electrodes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0816—Cards, e.g. flat sample carriers usually with flow in two horizontal directions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0829—Multi-well plates; Microtitration plates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
- G01N35/02—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
- G01N35/04—Details of the conveyor system
- G01N2035/0439—Rotary sample carriers, i.e. carousels
- G01N2035/0458—Multiple concentric rows of wells
Definitions
- the present invention relates to kits for quick and precise detection, identification and quantification of small molecules and macromolecules, such as proteins, peptides, antibodies, nucleic acid markers, hormones, metabolites, carbohydrates, lipids and other analytes of interest, in liquid samples.
- small molecules and macromolecules such as proteins, peptides, antibodies, nucleic acid markers, hormones, metabolites, carbohydrates, lipids and other analytes of interest.
- the disclosed kits may be used for research, clinical applications, diagnosis and treatment.
- the present invention also relates to a system for quick and precise detection, identification and quantification of small molecules and macromolecules, such as proteins, peptides, antibodies, nucleic acid markers, hormones, metabolites, carbohydrates, lipids and other analytes of interest, in liquid samples, and to methods of analyte detection and quantification that comprise the use of the disclosed system.
- small molecules and macromolecules such as proteins, peptides, antibodies, nucleic acid markers, hormones, metabolites, carbohydrates, lipids and other analytes of interest, in liquid samples, and to methods of analyte detection and quantification that comprise the use of the disclosed system.
- the disclosed system may be used for research, clinical applications, and for diagnosis and treatment purposes.
- kits and methods that quickly and reliably detect and quantify proteins and other analytes for research and for diagnosis and preventive and therapeutic guidance.
- the present application presents a solution to the aforementioned challenges by providing kit components that can be fit into various automated liquid handling systems, and provide rapid and highly efficient measurements of macromolecules.
- kits that fit into automated liquid handling systems and provide rapid and highly efficient multiplex detection and quantification of small molecules and macromolecules, such as proteins, peptides, antibodies, nucleic acids, biomarkers, hormones, metabolites, carbohydrates and lipids of interest, in liquid samples.
- the disclosed kits may be used on microquantities of liquid samples for a large number of tests, such as immunoassays, nucleic acid tests, clinical diagnostics, biomarker detection, and proteomic profiling, with no or limited manual interventions from the user.
- kits for automated and pre-programmed singleplex and multiplex analyte detection and quantification from liquid samples are provided herein.
- kits may include one or more of a chip caddy, consumable assay chips, an electrode assembly, a connector assembly comprising a lid and a printed circuit board (PCB) interface, cables, a voltage power supply, a vacuum pump, a vacuum trap, and custom-designed fluid delivery and aspiration manifolds fitting different size liquid handling robot arms, and may further comprise one or more buffers, reagents and instructions for use.
- a chip caddy consumable assay chips
- an electrode assembly comprising a lid and a printed circuit board (PCB) interface
- cables a voltage power supply
- a vacuum pump a vacuum trap
- custom-designed fluid delivery and aspiration manifolds fitting different size liquid handling robot arms
- kits provided herein are configured to fit into different automated systems for singleplex or multiplex detection and quantification of macromolecules, and to be connected to different types of automated imagers. Moreover, the disclosed components of the kits provided herein are configured to be used for a large number of tests, such as immunoassays, nucleic acid tests, multiplexed protein measurements, clinical diagnostics, biomarker detection, and proteomic profiling, for the detection and quantification of proteins, nucleic acids, biomarkers, hormones, metabolites, carbohydrates and lipids of interest, in liquid samples. Liquid samples may vary in volume from about 0.2 pi to about IOOOmI.
- Suitable automated imagers may comprise a LED or laser- induced fluorescence imaging reader equipped with fluorescence excitation sources, optical filters, a photon measurement system (such as a camera or a photomultiplier tube system), objective lenses, exposure and light intensity active monitoring and regulation systems, and automated image analysis and reporting systems.
- the assay chips are microfluidic chips that comprise glass or one or more polymers.
- the assay chips are functionalized printed circuit boards (PCBs).
- the assay chips are paper-based and comprise cellulosic materials such as organic fibers.
- the chip caddy in the disclosed kits is configured to contain assay chips.
- the consumable assay chips are single use chips.
- the consumable assay chips are reusable chips.
- the assay chips are configured to comprise wells designed to accept multiple samples and reagents for multiplex analyte detection and quantification.
- the chip caddy comprises one or more metals, such as aluminum, a polymer, or any mixture thereof.
- the chip caddy in the disclosed kits is configured to contain 1 or more chips.
- each chip contains 2 sample wells.
- each chip caddy contains 16 sample wells, 64 sample wells, 256 sample wells, 640 sample wells, 1280 sample wells, 3200 sample wells, or 6400 sample wells.
- each well has a diameter from about 1 mm to about 5 mm, or from about 1.5 mm to about 3 mm.
- two or more wells are connected via channels.
- the electrode assembly is configured to fit into the connector assembly and to hold consumable assay chips.
- the electrode assembly is configured to comprise a hinged precision electrode interface connectable to the programmable voltage power supply.
- the voltage power supply may comprise from one to ten independent outputs.
- the electrode assembly is configured to comprise a bottom component housing a spring mechanism configured to align a chip caddy within the electrode assembly and a top lid comprising an insulating electrode frame holding electrode rails.
- the electrode rails are configured to be straight and aligned flat and parallel to the chip caddy.
- the electrode assembly is configured to be in open or closed position.
- the electrode assembly is configured to be removable from the connector assembly. In some embodiments, the electrode assembly can be washed, bleached and disinfected and used for additional tests.
- the connector assembly is configured to be attachable to an automated liquid handling robot’s base. In some embodiments, the connector assembly is configured to transmit electricity to the electrode rails within the electrode assembly.
- each electrode in the electrode rails is configured to sit on the edge of each well and to receive electricity through the connector assembly.
- each electrode has a thickness between 0.1 mm and 1 mm, or between 0.3 mm and 0.7 mm.
- each electrode is a laser-welded platinum electrode comprising an angled top.
- the vacuum pump and the vacuum trap are configured to be connectable to a programmable voltage power supply.
- the voltage power supply may comprise from one to ten independent outputs.
- the software is configured to integrate and connect the liquid handling robot, the vacuum system, and the voltage power supply to fully automate the assay running steps and enable advanced data analysis.
- the software is configured to integrate and connect the liquid handling robot, the vacuum system, the voltage power supply and the imaging system, to fully automate the assay running steps and readout, and enable image analysis and advanced data analysis.
- the custom-designed fluid delivery and aspiration manifolds in the disclosed kits are configured to be connectable to a vacuum line and for macro tip or micro tip attachment.
- the disclosed components of the kits provided herein are configured to hold the consumable chips in place and maintain electrical conductivity within the wells in the chips.
- the automated liquid handling robot is configured to deliver or aspirate one or more assay reagents in appropriate sequence to one or more wells in the consumable chips.
- the disclosed kit components are configured to fit into an automated analyte detection and quantification system with direct sampling capabilities.
- the disclosed system comprises an automated liquid handling robot and an assay subunit.
- the automated liquid handling robot is a custom-designed robot having microliter pipetting capabilities, and programmed to deliver, add, aspirate or remove liquids from sample wells at defined time intervals or in pre-determined conditions.
- the liquid handling robot is capable of automatically carrying out all necessary sample preparation steps before an assay, such as reagent mixing and sample dilutions.
- the automated liquid handling robot comprises a custom- designed arm comprising an aspiration manifold connected to a vacuum line and configured for micro tip attachment.
- the system comprises the connector assembly, the electrode assembly configured to fit in the connector assembly and to hold consumable assay chips, and comprising a hinged precision electrode interface, the vacuum pump, and the programmable voltage power supply comprising one to ten independent outputs connected to the electrode interface.
- an automated imager is integrated with the system.
- the automated imager is separate from the system.
- the automatic imager comprises a LED or laser-induced fluorescence imaging reader equipped with fluorescence excitation channels, optical filters, a photon measurement system, such as camera or a photomultiplier tube system, objective lenses, systems for autofocus, auto-exposure, light intensity monitoring and regulation, and automated image analysis and reporting systems.
- the software integrates and connects the liquid handling robot, the vacuum system, the voltage power supply and the imaging system, to enable image analysis and advanced data analysis.
- the automated liquid handling robot is configured to deliver or aspirate one or more assay reagents in appropriate sequence to one or more wells in the consumable chips.
- the disclosed automated system is configured to detect the presence of one or more analytes of interest in a liquid sample and quantify detected amounts of one or more analytes within a period of time from about 10 minutes to about 4 hours.
- Liquid samples may include, but are not limited to, biological samples, such as blood, serum, and urine, cell suspensions, cell supernatants and lysates, plant extracts, sea water, microfilm fluids, running water, and beverages.
- the disclosed automated system is configured to detect and quantify macromolecules, such as proteins, peptides, antibodies, nucleic acids, biomarkers, hormones, metabolites, carbohydrates and lipids of interest, from liquid samples. Suitable detection methods include, but are not limited to, immunoassays, nucleic acid tests, clinical diagnostics, biomarker detection, and proteomic profiling.
- the disclosed automated system is configured to allow one or more liquid samples and one or more reagents to be introduced separately and at different times into the system.
- the disclosed automated system is configured to detect and quantify one or more analytes in liquid samples that are in an amount from about 0.2pl sample to about IOOOmI sample. Additionally, the disclosed automated system is configured to detect and quantify one or more analytes within a period of time, such as from about 10 minutes to about 4 hours.
- the disclosed automated system is configured to apply directional electric field to the assay chips, such that one or more reagents are electrokinetically and sequentially transported from one well to the other.
- the disclosed automated system is also configured to allow the liquid handling robot to precisely transfer, dispense into, deliver to or aspirate from different samples one or more reagents at different times or in different cycles, in order to carry out sample preparation steps, or capture and bind target analytes.
- capturing and binding target analytes may include, but are not limited to, sandwich antibody detection, enzyme-labeled antigen reaction, fluorometric detection, in situ hybridization, microarray technology, affinity binding, radioactive and colorimetric binding.
- an automated system and automated methods for rapid and highly efficient multiplex detection and quantification of small molecules and macromolecules, such as proteins, peptides, antibodies, nucleic acids, biomarkers, hormones, metabolites, carbohydrates and lipids of interest, from liquid samples.
- the disclosed automated system and methods may be used on microquantities of liquid samples for a large number of tests, such as immunoassays, nucleic acid tests, multiplex diagnostics, biomarker detection, and proteomic profiling, with no or limited manual interventions from the user.
- an automated analyte detection and quantification system with direct sampling capabilities.
- the disclosed system comprises an automated liquid handling robot and an assay subunit.
- the automated liquid handling robot is a custom-designed robot having microliter pipetting capabilities, and programmed to deliver, add, aspirate or remove liquids to and from sample wells at defined time intervals or in pre-determined conditions.
- the automated liquid handling robot comprises a custom- designed and manufactured arm comprising an aspiration manifold connected to a vacuum line and configured for micro tip attachment.
- the assay subunit is a system that comprises a connector assembly comprising a lid and a printed circuit board (PCB) interface with conductive pins, an electrode assembly configured to fit into the connector assembly and to hold consumable assay chips, and comprising a hinged precision electrode interface, a vacuum pump, and a programmable, software-controlled voltage power supply connected to the electrode interface comprising from one to ten independent outputs.
- PCB printed circuit board
- an automated imager is integrated into the system.
- the automated imager is separate from the system.
- the automatic imager comprises a LED or laser-induced fluorescence imaging reader, which may be equipped with a microscope, fluorescence excitation channels, optical filters, a photon measurement system, objective lenses, systems for autofocus, auto exposure, light intensity active monitoring and regulation, and an automated image analysis and reporting system.
- the software is configured to integrate and connect the liquid handling robot, the vacuum system, the voltage power supply and the imaging system, to enable image analysis and advanced data analysis.
- the connector assembly is fixed to a plate at the automated liquid handling robot’s base.
- the hinged precision electrode interface comprises multiple electrode rails.
- the connector assembly is configured to transmit electricity to the electrode rails within the electrode assembly.
- the electrode assembly comprises a bottom component housing a spring mechanism configured to align a chip caddy within the electrode assembly, and a top lid comprising an insulating electrode frame holding the electrode rails.
- the electrode rails are configured to be straight and aligned flat and parallel to the chip caddy.
- the electrode assembly is configured to be in either an open or closed position.
- the electrode assembly is removable from the connector assembly. In some embodiments, the electrode assembly can be washed, bleached, disinfected and reused.
- the assay chips are microfluidic chips comprising glass or one or more polymers. In some embodiments the assay chips comprise functionalized microcapillaries composed of glass and/or polymer. In some embodiments the assay chips are functionalized printed circuit boards (PCBs). In some embodiments, the assay chips are paper- based devices comprising cellulosic materials, such as organic fibers. [0049] In some embodiments, the consumable assay chips are contained in a chip caddy. In some embodiments, the consumable assay chips are single use chips. In some embodiments, the consumable assay chips are reusable chips. The consumable assay chips contain wells designed to accept multiple samples and reagents for multiplex analyte detection and quantification.
- the chip caddy comprises one or more metals, such as aluminum, one or more polymers such as plastic, or any mixture thereof.
- the chip caddy contains 1 or more microfluidic chips or assay chips.
- each chip contains 2 sample wells.
- each chip caddy contains 16 sample wells, 64 sample wells, 256 sample wells, 640 sample wells, 1280 sample wells, 3200 sample wells, or 6400 sample wells.
- each well has a diameter from about 1 mm to about 5 mm, or from about 1.5 mm to about 3 mm.
- two or more wells are connected by channels.
- each electrode in the electrode rails is configured to sit on the edge of each well and to receive electricity through the connector assembly.
- each electrode has a thickness between 0.1 mm and 1 mm, or between 0.3 mm and 0.7 mm.
- each electrode is a laser-welded platinum electrode comprising an angled top.
- the assay subunit is configured to hold the consumable chips in place and maintain electrical conductivity within the wells in the chips.
- the automated liquid handling robot is configured to deliver or aspirate one or more assay reagents in appropriate sequence to one or more wells in the consumable chips.
- the disclosed automated system is configured to detect the presence of one or more analytes of interest in a liquid sample and quantify detected amounts of one or more analytes within a period of time from about 10 minutes to about 4 hours.
- Liquid samples may include, but are not limited to, biological samples, such as blood, serum, and urine, cell suspensions, cell supernatants and lysates, plant extracts, sea water, microfilm fluids, running water, and beverages.
- the disclosed automated system is configured to detect and quantify macromolecules, such as proteins, peptides, antibodies, nucleic acids, biomarkers, hormones, metabolites, carbohydrates and lipids of interest, from liquid samples.
- macromolecules such as proteins, peptides, antibodies, nucleic acids, biomarkers, hormones, metabolites, carbohydrates and lipids of interest.
- Suitable detection methods include, but are not limited to, immunoassays, nucleic acid tests, multiplex diagnostics, biomarker detection, and proteomic profiling.
- the disclosed automated system is configured to allow one or more liquid samples and one or more reagents to be introduced separately and at different times into the system.
- the disclosed automated system is configured to detect and quantify one or more analytes in liquid samples that are in a volume amount from about 0.2pl to about IOOOmI.
- the disclosed automated system is configured to apply directional electric field to the electrode assembly, such that one or more reagents are electrokinetically and sequentially transported through the system to the one or more samples.
- the disclosed automated system is also configured to allow the liquid handling robot to precisely transfer, dispense into, deliver to or aspirate from different samples one or more reagents at different times or in different cycles, in order to capture and bind target analytes.
- capturing and binding target analytes may include, but are not limited to, sandwich antibody detection, enzyme-labeled antigen reaction, fluorometric detection, in situ hybridization, microarray technology, affinity binding, radioactive and colorimetric binding.
- the disclosed automated methods comprise (a) separately introducing the liquid sample and one or more reagents into an automated analyte detection and quantification system with direct sampling capabilities as described above; (b) choosing an assay protocol from a list of pre-validated assay protocols to detect and quantify one or more target analytes; (c) closing the connector assembly and the electrode assembly underneath the connector assembly; (d) starting the automated system; (e) waiting 10 to 240 minutes; and (f) calculating target analyte concentrations from detection and quantification data presented by the automated system.
- FIG. 1 A illustrates a diagram showing an example liquid handling robot.
- FIG. IB illustrates a diagram showing control of system components.
- FIGS. 2Aand 2B illustrate diagrams showing delivery of consumables into sample wells.
- FIGS. 3A, 3B and 3C illustrates examples of four assay chips in a caddy.
- FIGS. 4A and 4B illustrate a diagram showing a close-up view of the electrodes an electrode assembly.
- FIGS. 5A, 5B, 5C and 5D illustrate diagrams showing assemblies in an open position.
- FIGS. 6A and 6B illustrate diagrams showing assembly with conductive pins.
- FIG. 7. illustrates a diagram showing an example vacuum arm designed to fit the liquid handling robot.
- FIGS. 8A and 8B illustrate diagrams showing the connector assembly in the open position.
- FIGS. 9A, 9B and 9C illustrate diagrams showing examples of the connector assembly in modes of operation.
- FIGS. 10A, 10B illustrate diagrams showing the electrode assembly in modes of operation
- FIG. IOC illustrates a diagram showing the chip caddy in a mode of operation.
- FIG. 11 A - 1 ID illustrate diagrams showing the electrode frame and electrode rails in the electrode assembly.
- FIGS. 12A, 12B and 12C illustrate diagrams showing views of the electrode frame and electrode rail placement.
- FIGS. 13 A and 13B illustrate diagrams showing placement of electrode tips and electrode rail placement.
- FIG. 14 illustrates a diagram showing a detailed view of the electrode and pipette tip placement.
- FIG. 15 illustrates a diagram showing a standard curve for the human IL-1 Beta assay.
- FIG. 16 illustrates a flowchart of a method for an automated method for singleplex and multiplex detection and quantification of one or more analytes in a liquid sample.
- FIG. 17 illustrates a flowchart of a method for an automated method for singleplex and multiplex detection and quantification of one or more analytes in a liquid sample.
- the numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth, used to describe and claim certain embodiments are to be understood as being modified in some instances by the term "about” or “approximately.” For example, “about” or “approximately” can indicate +/- 20% variation of the value it describes. Accordingly, in some embodiments, the numerical parameters set forth herein are approximations that can vary depending upon the desired properties for a particular embodiment. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of some examples are approximations, the numerical values set forth in the specific examples are reported as precisely as practicable. The recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range.
- Administer or Apply To provide or give a subject a composition, such as a pharmaceutical composition, by an effective route.
- routes of administration include, but are not limited to, parenteral, topical, transdermal, oral, intravenous, and muscular routes.
- Analog A compound having a structure similar to another, but differing from it, for example, in one or more atoms, functional groups, or substructure.
- Antagonist A molecule that, upon binding to a cell receptor, competes and/or interferes with one or more ligands binding the same receptor, and thus reduces or prevents a response elicited by those ligands.
- Antibiotic A chemical substance capable of treating bacterial infections by inhibiting the growth of, or by destroying existing colonies of bacteria and other microorganisms.
- Antibody An immunoglobulin capable of specifically binding a target molecule, such as a carbohydrate, a polynucleotide, a lipid, or a polypeptide, via one or more antigen recognition sites, located in the variable region of the immunoglobulin molecule.
- the term “antibody” includes polyclonal and monoclonal antibodies, fragments thereof, such as Fab, Fab', F(ab')2 and Fv, single chain variable fragments (ScFv), mutants thereof, fusion proteins comprising an antibody portion, and any other modified configuration of the immunoglobulin molecule that comprises an antigen recognition site.
- Antibodies can be distinguished into five major classes, IgA, IgD, IgE, IgG, and IgM, according to the amino acid sequence of the constant domain in their heavy chains.
- Monoclonal antibodies are obtained from a substantially homogeneous population of antibodies, and specifically target a single epitope (determinant) of an antigen.
- Polyclonal antibodies target different epitopes on the antigen.
- the heavy and light chains of an antibody each comprise a variable region and a constant region.
- the variable regions of the heavy and light chain each consist of four framework regions (FR) connected by three complementarity determining regions (CDRs), also known as hypervariable regions. The CDRs in each chain are held together in close proximity by the FRs and form the antibody’s antigen-binding site.
- FR framework regions
- CDRs complementarity determining regions
- Antibody-drug conjugate Complex molecules composed of an antibody linked to a biologically active cytotoxic payload or drug. By combining the targeting capabilities of monoclonal antibodies with the cancer-killing ability of cytotoxic drugs, antibody- drug conjugates allow for discrimination between healthy and diseased tissue. Unlike traditional chemotherapeutic drugs, antibody-drug conjugates target only cancer cells so that healthy cells are less severely affected.
- Anti-Fungal Agent An active agent capable of inhibiting the growth of or destroying fungi.
- Anti-inflammatory agent An active agent that reduces inflammation and swelling.
- Anti-Oxidant An active agent that inhibits oxidation or reactions promoted by oxygen or peroxides.
- Anti-Protozoal Agent An active agent capable of inhibiting the growth of or destroying protozoa microorganisms.
- Anti- Viral Agent An active agent that inhibits the replication of or destroys viruses.
- Cancer A condition characterized by unregulated cell growth.
- cancer include, but are not limited to, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, gastrointestinal cancer, Hodgkin's and non-Hodgkin's lymphoma, pancreatic cancer, glioblastoma, cervical cancer, glioma, ovarian cancer, liver cancer such as hepatic carcinoma and hepatoma, bladder cancer, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney cancer such as renal cell carcinoma and Wilms' tumors, basal cell carcinoma, melanoma, prostate cancer, thyroid cancer, testicular cancer, esophageal cancer, and various types of head and neck cancer.
- Chemotherapeutic agent or Chemotherapy A chemical agent with therapeutic usefulness in the treatment of diseases characterized by abnormal cell growth. Such diseases include tumors, neoplasms, and cancer.
- a chemotherapeutic agent is a radioactive compound.
- a chemotherapeutic agent is a biologic, such as a monoclonal antibody.
- a subject treated with an active agent using the disclosed methods is, will be, or was previously treated with chemotherapy.
- Exemplary chemotherapeutic agents are provided in Slapak and Kufe, Principles of Cancer Therapy, Chapter 86 in Harrison's Principles of Internal Medicine, 14th edition; Perry et ah, Chemotherapy, Ch.
- Chimeric Antibody An antibody having a variable region or part of variable region from a first species of a mammal and a constant region from a second species of a mammal.
- Congenital Disorder A condition or disease present at birth, which is inherited or brought about by environmental factors, such as the mother’s alcohol or drug consumption, nutritional intake and placental health.
- congenital disorders include, but are not limited to, congenital heart defect, cleft lip, sickle cell disease, alpha-thalassemia, beta- thalassemia, spinal muscular atrophy, spina bifida and Down syndrome.
- Consumables Laboratory equipment and reagents that must be replaced regularly as they wear out or are used. Consumable may include, but are not limited to, reagents, buffers, disposable test tubes, beakers, pipettes, strips, gloves, facemasks, sample containers, syringes, centrifuge tubes, and swabs.
- Contacting Placement in direct physical association; includes both in solid and liquid form. Contacting can occur in vitro with isolated cells (for example in a tissue culture dish or other vessel) or in vivo by administering an active agent to a subject.
- Control A reference standard.
- a control is a known value or range of values, such as one indicative of the presence or the absence of cystic fibrosis.
- a control is a value or range of values, indicating a response in the absence of a therapeutic agent.
- Cytokine A substance released by one cell population that acts on another cell as intercellular mediator.
- cytokines include, but are not limited to, lymphokines, monokines; interleukins (ILs) such as IL-1, IL-la, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12, IL-15, including PROLEUKIN® rIL-2; a tumor necrosis factor such as TNF-a or TNF-b; and other polypeptide factors including LIF and kit ligand (KL).
- ILs interleukins
- Cytotoxic agent A substance that inhibits or prevents the function of cells and/or causes destruction of cells.
- Domain A distinct functional and/or structural unit of a protein.
- a conserved domain refers to a domain that has been conserved during evolution. During evolution, changes at specific positions of an amino acid sequence in the protein have occurred in a way that preserve the physico-chemical properties of the original residues, and hence the structural and/or functional properties of that region of the protein.
- Drug or Active Agent A chemical substance or compound that induces a desired pharmacological or physiological effect, and includes therapeutically effective, prophylactically effective, or systematically effective agents.
- the terms also encompass pharmaceutically acceptable, pharmacologically active derivatives and analogs of those active agents specifically mentioned herein, including, but not limited to, salts, esters, amides, pro-drugs, active metabolites, inclusion complexes, analogs, and the like.
- Suitable active agents that may be incorporated into the pharmaceutical compositions provided herein include, but are not limited to, adrenergic agents; adrenocortical steroids; adrenocortical suppressants; alcohol deterrents; aldosterone antagonists; amino acids; ammonia detoxicants; anabolic agents; analeptic agents; analgesic agents; androgenic agents; anesthetic agents; anorectic compounds; anorexic agents; antagonists; anterior pituitary activators and anterior pituitary suppressants; anti-acne agents; anti -adrenergic agents; anti allergic agents; anti-amebic agents; anti-androgen agents; anti-anemic agents; anti-anginal agents; anti-anxiety agents; anti-arthritic agents; anti-asthmatic agents and other respiratory drugs; anti- atherosclerotic agents; anti-bacterial agents; anti-cancer agents, including antineoplastic drugs, and anti-cancer supplementary potentiating agents; anticho
- Effective amount The amount of an active agent (alone or with one or more other active agents) sufficient to induce a desired response, such as to prevent, treat, reduce and/or ameliorate a progressive degenerative disorder.
- Effective amounts of an active agent, alone or with one or more other active agents can be determined in many different ways, such as assaying for a reduction in of one or more signs or symptoms associated with the condition, such as an uncontrolled inflammatory response condition, in the subject or measuring the level of one or more molecules associated with the condition to be treated.
- Hydrogel A water-swellable polymeric matrix that can absorb a substantial amount of water to form elastic gels.
- the matrix is a three-dimensional network of macromolecules held together by covalent or non-covalent crosslinks. Upon placement in an aqueous environment, dry hydrogels swell to the extent allowed by the degree of cross-linking.
- Hydrophilic A polymer, substance or compound that is capable of absorbing more than 10%/w of water at 100% relative humidity (rh).
- Hydrophobic A polymer, substance or compound that is capable of absorbing no more than 1%/w of water at 100% relative humidity (rh).
- Hygroscopic A polymer, substance or compound that is capable of absorbing more than 20 wt % of water at 100% relative humidity (rh).
- Inhibiting a condition Reducing, slowing, or even stopping the development of a condition, for example, in a subject who is at risk of developing or has a particular condition, such as a progressive genetic disease.
- Interferon-type I a large group of interferon proteins that bind to interferon receptors and regulate the activity of the immune system.
- Lipophilic A substance or compound that has an affinity for a non-polar environment compared to a polar or aqueous environment.
- MicroRNAs Short, highly conserved small noncoding RNAmolecules naturally occurring in the genomes of plants and animals. miRNAs are 17-27 nucleotides long and regulate posttranscriptional mRNA expression, typically by binding to the 3’ untranslated region (3’-UTR) of the complementary mRNA sequence, resulting in translational repression and gene silencing. miRNAs function in tumor suppression as oncogenes, and altered expression of particular miRNAs has been implicated in the onset and development of cancer.
- Multiplex Analysis Any analysis of two or more analytes in a sample, wherein each analyte is different from one another.
- the methods disclosed herein may include multiplex analysis of 2 or more, 5 or more, 10 or more, 50 or more, 100 or more, 500 or more or 1000 or more analytes in a sample.
- Oil Any fatty substance that is in liquid form at room temperature (25° C) and at atmospheric pressure (760 mmHg).
- An oily phase in a pharmaceutical composition may comprise at least one polar or apolar hydrocarbon-based oil.
- Parenteral a type of administration that includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques.
- Compositions for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions prior to use.
- Pathogen An infectious agent capable of invading a host, which is transmitted through the air, sex, blood, and other bodily fluids, or through the fecal-oral route. Common pathogens include viruses, such as the human immunodeficiency virus (HIV) and hepatitis C; bacteria; fungi, such as yeast, mold, and mushrooms; and parasites, such as protozoa, helminths, and ectoparasites.
- HAV human immunodeficiency virus
- fungi such as yeast, mold, and mushrooms
- parasites such as protozoa, helminths, and ectoparasites.
- Permeation Enhancer A natural or synthetic molecule that facilitates the transport of co-administered active agents across biological membranes.
- pH Modifier A molecule or buffer used to achieve desired pH control in a formulation.
- exemplary pH modifiers include acids (e.g., acetic acid, adipic acid, carbonic acid, citric acid, fumaric acid, phosphoric acid, sorbic acid, succinic acid, tartaric acid, basic pH modifiers (e.g., magnesium oxide, tribasic potassium phosphate), and pharmaceutically acceptable salts thereof.
- compositions and formulations suitable for pharmaceutical delivery of the compositions herein disclosed are conventional. Remingtons’ Pharmaceutical Sciences , by E. W. Martin, Mack Publishing Co., Easton, PA, 19th Edition (1995), describes compositions and formulations suitable for pharmaceutical delivery of the compositions herein disclosed.
- the nature of the carrier can depend on the particular mode of administration being employed. For instance, parenteral applications usually include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle.
- parenteral compositions may also contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like.
- Proinflammatory cytokines cytokines produced predominantly by activated macrophages and involved in the up-regulation of inflammatory reactions.
- Exemplary proinflammatory cytokines include, but are not limited to, IL-Ib, IL-6, and TNF-a.
- IL-Ib is released primarily by monocytes and macrophages during cell injury, infection, invasion, and inflammation.
- Subject A living multi-cellular vertebrate organism, a category that includes human and non-human mammals, as well as birds (such as chickens and turkeys), fish, and reptiles. Exemplary subjects include mammals, such as human and non-human primates, rats, mice, dogs, cats, rabbits, cows, pigs, goats, horses, and the like.
- Body Surface A surface located on the human body or within a body orifice.
- a “body surface” includes, by way of example, skin, teeth, skin or mucosal tissue, including the interior surface of body cavities that have a mucosal lining.
- Topical administration Delivery of an active agent to a body surface, such as, the skin or mucosa, as in, for example, topical drug administration in the prevention or treatment of various skin disorders.
- Toxic agent An agent or substance that can produce an adverse biological effect.
- Atoxic agent may be chemical, physical, or biological in nature.
- Toxic agents include, but are not limited to, inorganic substances such as lead, mercury, hydrofluoric acid, cyanide, and chlorine gas, organic compounds such as alcohol, radiations, coal dust, asbestos fibers, finely divided silicon dioxide, plant and pathogen toxins, snake venom, lithium and abused substances, such as marijuana and cocaine.
- Transdermal A route of administration by which active ingredients are delivered across the skin for systemic distribution. Examples include transdermal patches for drug delivery.
- Water-Insoluble A polymer, compound or composition with a solubility in water of less than 5%/w, less than 3%/w, or less than 1%/w, as measured in water at 20°C.
- Water-Swellable A polymer, substance or compound, that may absorb an amount of water greater than at least 25%/w of its own weight, or greater than at least 50%/w, upon immersion in an aqueous medium.
- FIGS. 1 A and IB show a diagram showing an example robot configuration (FIG. 1 A) and the assay sub-unit (FIG. IB) of an automated analyte detection and quantification system with direct sampling capabilities.
- the liquid handling robot may include a frame 8 for holding the robotic components.
- the robot may include a multichannel liquid handling pipette 1, a vacuum arm with removable pipette tips 2, integrated components 3 (e.g., power supply and vacuum pump), an open position for connector assembly 4, position for electrode assembly 5, an imaging unit 6 (which may be integrated with the robot, or and external imaging unit), and an associated computer 7.
- the sub-unit occupies one position within the “deck” of the robot layout, whereas reagents, pipette tips, or other consumables occupy other areas within the robot layout.
- the box and internal components are controlled via a computer and software. Communications may be in a wired or wireless format.
- the vacuum part 12 may designed to fit to a liquid handling control arm. The arm may move in 3 dimensions (e.g., in an x, y, z space) to remove liquid from wells.
- the vacuum part may have multiple tips, such as 8, 12, 16 or hundreds of tips.
- the pipettor of the liquid handling robot travels back and forth between the sub unit and other locations on the robot deck and carries out pre-programmed assay functions. Liquids are delivered to the wells (or micro-wells) within the assay consumables, which are placed within the assay sub-unit. All assay functions are carried out via the laptop computer shown on the far left in the robot layout.
- the sub-unit may include a connector assembly 9, electrode assembly 10 and a consumable chips & caddy 11.
- FIGS. 2A and 2B show delivery of consumables into sample wells of a chip caddy by individual pipette tips, which are guided and directed by the liquid handling robot. Electrode rails, which run diagonally in the image, do not interfere with the liquid delivery to the wells.
- FIGS. 3 A, 3B and 3C show four assay chips in a frame that can accommodate up to 128 samples at one time.
- the example chip caddy of FIG. 3 A may hold four assay chips.
- the chip caddy is compatible with most biological buffers and chemicals, so chips can be installed to the caddy and stored in wet conditions.
- Each well in the customized assay chip has a diameter of approximately 2mm and can hold about 2.5pl of volume.
- the assay chips are seated within the assay sub-unit.
- the 256 wells may be 2 mm sized.
- a corresponding number of electrodes would be used to apply voltage into the wells. In one example, considering the wells are 2 mm, electrodes may be in .5 mm and pipette tips are 07mm.
- FIGS. 4A and 4B the figures provide a close-up view of the electrodes, which are a part of the electrode assembly and transmit electricity from the voltage power supply to the fluid-filled wells.
- the position of the electrodes in the system does not interfere with the liquid delivery from pipette tips.
- FIGS. 5A, 5B, 5C and 5D the figures provide a view of the connector assembly (A), and electrode assembly (B, C) in their open positions.
- a hinged frame containing the electrodes makes contact with a hinged electrical connector in the connector assembly, which applies voltage through a series of conductive pins.
- the consumable chip is housed at the bottom of the assembly (5D).
- FIGS. 6A and 6B the figures show the conductive pins, which are integral components of the connector assembly. These pins direct voltage from the power supply cable onto the electrode rails.
- FIG. 7 shows an example of a vacuum arm custom- designed to fit the liquid handling robot.
- a set of removable pipette tips can be attached to the bottom of the vacuum arm.
- FIGS. 8 A and 8B the figures show the connector assembly in the open position.
- the apparatus 900 may have a base 902 with a section or portion of the base 902 configured to receive or hold a chip caddy.
- the apparatus 900 may include a hingedly attached electrode assembly 904 attached to a portion of the apparatus 900.
- the apparatus may have a hingedly attached lid 906 that may be secured via a screw mechanism 908 with a post 910.
- the apparatus may have a raised bed 912 where the electrode assembly 904 may rest upon when in the open position.
- FIGS. 10A, 10B and IOC the figures show the electrode assembly (A, B) in the open position, and the chip caddy (C), which is placed in the electrode assembly. Once the electrode assembly lid is closed, all electrodes are precisely positioned inside the corresponding wells of the assay chips and the electrical connectors are in contact with the electrode rails.
- FIGS. 11 A, 1 IB, 11C, and D the figures show the electrode frame 1100 and electrode rails 1102.
- the electrode rails have electrode tips 1104 spaced on the bottom portion of the electrode rail 1102.
- the electrode rail 1102 has end portions 1106 that clip the rail into position into frame 1100.
- FIG. 1 ID shows an example cross-sectional view of a portion of the electrode rail and an electrode tip.
- FIGS. 12A - 12C the figures show the electrode frame 1100 and electrode rails 1102.
- the insulating electrode frame holds 16 electrode rails.
- Spring mechanism enables easy installation and removal of the electrode rails.
- FIG. 12C illustrates the electrode frame 1100 with a detailed cross-sectional view of the location on which the electrode rails 1100 are positioned, and the spring mechanism which pushes the electrode rail in the electrode frame.
- FIGS. 13A and 13B show an example of electrodes placed in the wells of an assay chip.
- One electrode of a first electrode rail is placed in the waste well on the left side of the diagram, and a second electrode of a second electrode rail is placed in the sample well on the left side of the diagram.
- One electrode of a third electrode rail is placed in the waste well on the right side of the diagram, and a fourth electrode of a fourth electrode rail is placed in the sample well on the right side of the diagram.
- a voltage differential As between the first and second electrode rails there is applied a voltage differential.
- a first voltage is applied to the first electrode rail A of a predetermined value.
- a second voltage is applied to the second and third electrode rails B of a predetermined value.
- a conductive circuit connects the two middle (second and third) electrode rails.
- a third voltage is applied to the fourth electrode rail C.
- FIG. 13B shows that there is a gap between electrode rails between the assay chips.
- FIG. 14 the figure provides a detailed view of the electrodes.
- the electrodes are angled at the top to prevent collisions with the pipette tips during movement.
- FIG. 15 shows the standard curve for the human IL-1 Beta assay.
- Recombinant human IL1B was spiked into assay diluent at predetermined concentrations and the obtained calibrators were introduced into the disclosed system. 2.5pl of each calibrator was utilized within each sample well.
- the standard curve shows a broad dynamic range (5.5 log) with 1.9 pg/ml sensitivity.
- FIG. 16 the figure illustrates a method of an automated method for singleplex and multiplex detection and quantification of one or more analytes in a liquid sample.
- the method begins with separately introducing the liquid sample and one or more reagents into an automated analyte detection and quantification system with direct sampling capabilities (1610).
- the automated analyte detection and quantification system comprises a custom-designed automated liquid handling robot having microliter pipetting capabilities and programmed to deliver, add, aspirate or remove liquids to and from sample wells at defined time intervals or in predetermined conditions, and a system comprising a conductive connector assembly, an electrode assembly, a vacuum pump, a programmable, software-controlled voltage power supply and optionally an imaging system.
- the method continues with choosing an assay protocol from a list of pre-validated assay protocols to detect and quantify one or more target analytes (1620); closing the connector assembly and the electrode assembly within the connector assembly (1630); starting the automated system (1640); waiting 10 to 240 minutes to obtain data (1650); and calculating target analyte concentrations from the obtained data (1660).
- an assay protocol from a list of pre-validated assay protocols to detect and quantify one or more target analytes (1620); closing the connector assembly and the electrode assembly within the connector assembly (1630); starting the automated system (1640); waiting 10 to 240 minutes to obtain data (1650); and calculating target analyte concentrations from the obtained data (1660).
- FIG. 17 the figure illustrates a method of processing a fluid having sample molecules.
- the method beings with providing a chip caddy including a frame with one or more assay chips, the assay chips each including one or more rows of a plurality of pairs of wells, wherein the pair of wells are interconnected via channels (1710)
- Electrodes may be placed into the wells of the chip assays (1720), or the wells may have electrodes disposed within the body chip assay.
- a fluid including sample molecules, is placed into wells of the chip caddy such that the fluid contacts the electrodes (1730).
- a fluid may be placed into wells of the assay chips using a robotic controlled pipettor, having multiple pipettor tips, such that the fluid contacts an electrode positioned within the well.
- a predetermined voltage via the electrodes is applied to cause the fluid to move from a well into the channel. (1740).
- the fluid is aspirated from the wells using a vacuum controlled aspirator to remove fluid from the wells of the chip caddy (1750).
- kits for automated, pre-programmed, rapid and accurate singleplex or multiplex analyte detection and quantification in liquid samples are provided herein.
- kits may include one or more of a chip caddy, consumable assay chips, a clamshell-style electrode assembly, an connector assembly, cables, a voltage power supply, a vacuum pump, a vacuum trap, and custom-designed fluid delivery and aspiration manifolds fitting different size liquid handling robot arms, and may further comprise one or more buffers, reagents and instructions for use.
- These components are configured to fit different automated systems for singleplex or multiplex detection and quantification of macromolecules, and may be connected to different types of automated imagers. All components of the kit can be installed in only one direction and self-align: the assay consumables are placed into the electrode assembly, which fits under the connector assembly, which is then locked with fitting screws or a latch lock. Therefore, no training or expertise by the user is required.
- kits configured to be used for a large number of tests, such as immunoassays, nucleic acid tests, clinical diagnostics, biomarker detection, and proteomic profiling, for the detection and quantification of proteins, peptides, antibodies, nucleic acids, biomarkers, hormones, metabolites, carbohydrates and lipids of interest, in liquid samples.
- Liquid samples may vary in volume from about 0.2pl to about IOOOmI.
- Suitable automated imagers may comprise a LED or laser- induced fluorescence imaging reader equipped with features such as a fluorescence excitation source, optical filters, a photon measurement system, such as a camera or a photomultiplier tube system, objective lenses, systems for autofocus, auto-exposure, light intensity active monitoring and regulation, and automated image analysis and reporting systems.
- the chip caddy contains the consumable assay chips. These assay consumables may be single use chips or reusable chips. The consumable chips are configured to contain wells designed to accept multiple samples and reagents for multiplex analyte detection and quantification. [0160] The caddy is compatible with most biological buffers and chemicals, such that the assay chips can be installed to the caddy and stored in wet conditions.
- the chip caddy may contain 1 or more assay chips. Each assay chip may contain 2 sample wells, and each chip caddy may contain 16 sample wells, 64 sample wells, 256 sample wells, 640 sample wells, 1280 sample wells, 3200 sample wells, or 6400 sample wells. Each well has a diameter from about 1 mm to about 5 mm, or from about 1.5 mm to about 3 mm. Two or more wells may be connected via channels to allow for electric field-guided migration of reagents.
- the electrode assembly houses a hinged precision electrode interface, which comprises multiple electrode rails.
- the electrode assembly comprises a bottom metal component housing a spring mechanism configured to align a chip caddy within the electrode assembly, and a top lid comprising an insulating electrode frame holding the electrode rails.
- the electrode rails are configured to be straight and aligned flat and parallel to the chip caddy, such that all electrodes are positioned properly at the edge of each well.
- the electrode assembly is configured to be in either an open or closed position, and it has a specific configuration, such that it is configured to connect with the connector assembly.
- the electrode assembly can be washed, bleached, disinfected and reused as needed.
- the conductive connector assembly comprises a lid and a printed circuit board (PCB) interface.
- the electrode connector assembly is configured to interface with the electrode assembly and transmit electricity to the electrode rails within the electrode assembly, while providing space for liquid handling access to the assay chips.
- each electrode in the electrode rails is configured to sit on the edge of each well and to receive electricity through the connector assembly.
- Each electrode may have a thickness between 0.1 mm and 1 mm, or between 0.3 mm and 0.7 mm.
- each electrode is a laser-welded platinum electrode comprising an angled top to allow contact with the liquid in the wells and prevent collusion with automated microtips delivering or aspirating liquids to or from the wells.
- the connector assembly and electrode assembly are configured to hold the consumable chips in place and deliver and maintain electrical conductivity within all wells simultaneously with millimeter or sub-millimeter spatial accuracy.
- the voltage power supply may comprise from one to ten independent outputs for single or multiple connections and deliver a voltage from 0 to 5,000 volts.
- kits including the vacuum system and the voltage power supply, are configured to be integrated and connected to any software and imaging system linked to any automated system for singleplex or multiplex detection and quantification of macromolecules, to enable image analysis and advanced data analysis.
- kits are configured to enable detection and quantification of one or more analytes in liquid samples using any automated analysis system.
- Liquid samples may include, but are not limited to, biological samples, such as blood, serum, and urine, cell suspensions, cell supernatants and lysates, plant extracts, sea water, microfilm fluids, running water, and beverages. Liquid samples may be in a volume amount from about 0.2pl to about IOOOmI.
- Analytes may include, but are not limited to, proteins, peptides, antibodies nucleic acids, biomarkers, hormones, metabolites, carbohydrates and lipids, or other macromolecules of interest.
- Suitable detection methods include, but are not limited to, immunoassays, nucleic acid tests, clinical diagnostics, biomarker detection, and proteomic profiling.
- the components of the disclosed kits may be used with any automated liquid handling system to enable application of directional electric fields to electrokinetically and sequentially transport samples and/or reagents through the system. Additionally, the components of the disclosed kits are configured to allow any liquid handling robot to precisely transfer, dispense, deliver or aspirate liquids to and from sample wells at different times or in different cycles, in order to capture and bind target analytes. Capturing and binding target analytes may include, without limitations, sandwich antibody detection, enzyme-labeled antigen reaction, fluorometric detection, in situ hybridization, microarray technology, affinity binding, radioactive and colorimetric binding.
- kits may fit into an automated analyte detection and quantification system with direct sampling capabilities.
- This system automates detection and quantification workflows of macromolecules, such as proteins, peptides, antibodies, nucleic acid markers, hormones, metabolites, carbohydrates, lipids and other analytes of interest, including sample dilution, and provides complex sigmoidal plotting and curve fitting data from which the user can calculate target analyte concentrations, within 10 minutes to 4 hours time.
- the automated analyte detection and quantification system with direct sampling capabilities is a system in which all steps are automated and pre-programmed, such that little to no manual intervention is required.
- the automated analyte detection and quantification system with direct sampling capabilities is a system in which not all steps are automated and pre-programmed, such that some manual intervention may be required, for example, to move the chip caddy from a first location to a second location.
- the automated analyte detection and quantification system integrates microscale liquid handling, biomolecular measurement assay and data readout, such that the user only controls the system via external computer or integrated touch screen. Accordingly, the disclosed system may be operated by a person with minimal lab training in an automated fashion. Moreover, the disclosed automated analyte detection and quantification system performs multiplex analysis with high efficiency and with sub-pg/ml sensitivity, thus providing a solution to the aforementioned challenges.
- the disclosed system comprises an automated liquid handling robot and an assay subunit.
- the automated liquid handling robot is a custom-designed robot having microliter pipetting capabilities, and programmed to deliver, add, aspirate or remove liquids from sample wells at defined time intervals or in pre-determined conditions.
- the liquid handling robot is capable of automatically carrying out all necessary sample preparation steps before an assay, such as reagent mixing and sample dilution.
- the automated liquid handling robot comprises a custom-designed arm comprising an aspiration manifold configured to be connected to a vacuum line.
- the size of the manifold may be varied to adjust for attachment of macrotips or microtips, such that the robot delivers or aspirates reagents, buffers, or the like into sample wells as needed, with millimeter or sub-millimeter accuracy.
- the assay subunit comprises the conductive electrode connector assembly comprising a lid and a printed circuit board (PCB) interface, a clamshell-style electrode assembly configured to fit underneath and connect to the electrode connector assembly and to hold consumable assay chips, a vacuum pump, and a programmable voltage power supply connected to the connector interface.
- the electrode assembly houses a hinged precision electrode interface, which comprises multiple electrode rails. All components of the disclosed kits can be installed in only one direction and self-align: the assay chips are placed into the electrode assembly, which fits in place against the connector assembly, which is then locked with fitting screws or a latch lock. Therefore, no training or expertise by the user is required.
- the system may further comprise an automated imager.
- the automated imager may be placed directly underneath the assay subunit or it may be a separate unit.
- the automatic imager may comprise a fluorescence imaging reader equipped with features such as a fluorescence excitation channels, optical filters, a photon measurement system such as a camera or photomultiplier tube system), objective lenses, an autofocus system, auto exposure, light intensity monitoring/regulation systems, and automated image analysis and reporting systems.
- the voltage power supply may comprise one to ten independent outputs for single or multiple connections and deliver a voltage from 0 to 5,000 volts.
- the software is configured to integrate and connect the liquid handling robot, the vacuum system, and the voltage power supply, to fully automate the assay running steps and to enable image analysis and advanced data analysis.
- the power supply for example, may have 8 independent channels all of which can be operated independently. The channels can be used to apply voltage to the respective electrode assemblies.
- the voltage power supply may have a voltage in the 0-1500V range with a resolution of +/- 50mv; current of a 12mA total, 10mA max per channel with a 500nA resolution.
- the software is configured to connect the liquid handling robot, the vacuum system, the voltage power supply and the imaging system, to fully automate the assay running and imaging steps, and enable image analysis and advanced data analysis.
- the disclosed automated system is configured to detect the presence of one or more analytes of interest in a liquid sample and quantify detected amounts of one or more analytes within a period of time from about 10 minutes to about 4 hours.
- Liquid samples may include, but are not limited to, biological samples, such as blood, serum, and urine, cell suspensions, cell supernatants and lysates, plant extracts, sea water, microfilm fluids, running water, and beverages.
- Analytes may include, but are not limited to, proteins, peptides, antibodies, nucleic acids, biomarkers, hormones, metabolites, carbohydrates and lipids, or other macromolecules of interest.
- Suitable detection methods include, but are not limited to, immunoassays, nucleic acid tests, clinical diagnostics, biomarker detection, and proteomic profiling.
- the disclosed automated system is configured to allow one or more liquid samples and one or more reagents to be introduced separately and at different times into the system.
- Liquid samples may be in a volume amount from about 0.2 pi to about IOOOmI.
- the disclosed automated system is configured to apply directional electric field to the electrode assembly, such that one or more reagents are electrokinetically and sequentially transported through the system to the one or more samples.
- the disclosed automated system is also configured to allow the liquid handling robot to precisely transfer, dispense into, deliver to or aspirate from different samples one or more reagents at different times or in different cycles, in order to capture and bind target analytes.
- Capturing and binding target analytes may include, without limitations, sandwich antibody detection, enzyme-labeled antigen reaction, fluorometric detection, in situ hybridization, microarray technology, affinity binding, radioactive and colorimetric binding.
- kits disclosed herein provide accurate, rapid and effective detection and quantification of analytes in liquid samples.
- IL-1 Beta Measurements from Volume-Limited Renal Carcinoma Cells Treated with Different Drug Combinations
- ILl Beta is an Interleukin 1 family cytokine that plays an important role in inflammatory response. It is involved in cell proliferation, differentiation and apoptosis and, because of its potential to modulate acute inflammation, ILIB is a biomarker of interest for therapeutic applications and drug development safety assessments. In renal cell carcinoma, ILIB is one of the major mediators of local and systemic inflammation.
- ILIB was measured for biomarker-assisted therapy. Primary tumor cells were removed via micro-biopsy from clinical trial patients undergoing treatment for renal cell carcinoma. The tumor cells were then incubated in vitro with combinations of therapeutics to determine response and impact on secreted protein biomarkers. The goal of this study was to preserve precious samples from the tumor cells and compare the efficacy of microvolume immunoassays to conventional technology.
- the available sample volume that was tested for each condition was IOmI.
- IOmI sample a 2.5 pi aliquot was diluted 4 times into the assay diluent. From the resulting IOmI of total diluted sample, 2.5 pi were loaded into the sample wells. The remaining 7.5m1 of the original sample were preserved for future assays.
- the assay was completed in less than an hour from start to finish in a hands-free, fully automated manner. The data presented here were automatically calculated using analysis software.
- Example 1A A kit for automated and pre-programmed singleplexed and multiplexed detection and quantification of one or more analytes in a liquid sample, wherein the kit comprises one or more components, and wherein the one or more components comprise a chip caddy, consumable assay chips, an electrode assembly, an electrical connector assembly, one or more cables, a voltage supply, a vacuum pump, a vacuum trap, custom-designed manifolds, one or more buffers, reagents and instructions for use.
- the kit comprises one or more components, and wherein the one or more components comprise a chip caddy, consumable assay chips, an electrode assembly, an electrical connector assembly, one or more cables, a voltage supply, a vacuum pump, a vacuum trap, custom-designed manifolds, one or more buffers, reagents and instructions for use.
- Example 2A The kit of example 1A, wherein the components of the kit are configured to fit different automated systems and to allow for singleplex or multiplex detection and quantification of macromolecules, and to be connected to different automated imagers.
- Example 3A The kit of example 2A, wherein the components of the kit are configured to subject a liquid sample to an immunoassay, nucleic acid test, clinical diagnostic tests, biomarker detection, and/or multiplexed proteomic profiling.
- Example 4A The kit of example 3A, wherein the components of the kit are configured to subject a liquid sample to target analyte detection and quantification.
- Example 5A The kit of example 4A, wherein the target analyte is one or more of a protein, peptide, antibody, nucleic acid, biomarker, hormone, metabolite, carbohydrate or lipid.
- Example 6A The kit of example 5A, wherein the liquid sample is in a volume amount from about 0.2pl to about IOOOmI.
- Example 7A The kit of example 6A, wherein the automated imagers comprise one or more of a fluorescence excitation source, an optical filter, a photon measurement system, an objective lens, a system for autofocus, auto exposure, or light intensity monitoring and regulation, and an automated image analysis and reporting system.
- the automated imagers comprise one or more of a fluorescence excitation source, an optical filter, a photon measurement system, an objective lens, a system for autofocus, auto exposure, or light intensity monitoring and regulation, and an automated image analysis and reporting system.
- Example 8A The kit of example 7A, wherein the chip caddy contains 1 or more consumable assay chips.
- Example 9A The kit of example 8A, wherein the consumable chips are single use chips.
- Example 10A The kit of example 9A, wherein the consumable chips are reusable chips.
- Example 11 A The kit of example 8A, wherein the consumable chips comprise 2 sample wells, 16 sample wells, 64 sample wells, 256 sample wells, 640 sample wells, 1280 sample wells, 3200 sample wells, or 6400 sample wells.
- Example 12A The kit of example 11 A, wherein each well has a diameter from about 1 mm to about 5 mm, or from about 1.5 mm to about 3 mm, and wherein two or more wells are interconnected via channels.
- Example 13A The kit of example 1 A, wherein the electrode assembly is configured to fit in place under the connector assembly lid and to hold consumable assay chips.
- Example 14A The kit of example 13A, wherein the electrode assembly comprises a hinged precision electrode interface connectable to the programmable voltage power supply.
- Example 15 A The kit of example 14A, wherein the voltage power supply comprises from one to ten independent outputs.
- Example 16A The kit of example 15 A, wherein the electrode assembly comprises a bottom component housing a spring mechanism configured to align a chip caddy within the electrode assembly, and a top lid comprising an insulating electrode frame holding electrode rails.
- Example 17A The kit of example 16A, wherein the electrode rails are configured to be straight and aligned flat and parallel to the chip caddy.
- Example 18 A The kit of example 17A, wherein the electrode assembly is removable from the connector assembly.
- Example 19A The kit of example 18 A, wherein the electrode assembly is washable, bleachable, disinfectable and reusable.
- Example 20A The kit of example 19A, wherein the connector assembly comprises a lid and a printed circuit board (PCB) interface.
- PCB printed circuit board
- Example 21A The kit of example 20A, wherein the connector assembly is attachable to an automated liquid handling robot’s base and it is configured to transmit electricity to the electrode rails within the electrode assembly.
- Example 22 A The kit of example 21 A, wherein each electrode has a thickness between 0.1 mm and 1 mm, or between 0.3 mm and 0.7 mm.
- Example 23A The kit of example 22A, wherein each electrode is a laser-welded platinum electrode comprising an angled top.
- Example 24A The kit of example 23A, wherein the liquid handling robot, the vacuum system, the voltage power supply and the imaging system are configured to be integrated and connected by a custom software.
- Example 25 A The kit of example 1 A, wherein the custom-designed manifolds are configured to be connectable to a vacuum line and for macro tip or micro tip attachment.
- Example 26A The kit of example 25A, wherein the custom-designed manifolds are configured to be attached to an automated liquid handling robot to deliver or aspirate one or more assay reagents to one or more wells in the consumable chips.
- Example 27A The kit of example 1A, wherein the components of the kit are configured to fit into an automated analyte detection and quantification system with direct liquid sampling and sample dilution capabilities, and wherein the automated analyte detection and quantification system with direct liquid sampling and sample dilution capabilities comprises an automated liquid handling robot having microliter pipetting capabilities, programmed to deliver, add, aspirate or remove liquids to and from sample wells and assay chip wells at defined time intervals or in pre-determined conditions, and capable of automatically carrying out all sample preparation steps.
- an automated analyte detection and quantification system with direct liquid sampling and sample dilution capabilities comprises an automated liquid handling robot having microliter pipetting capabilities, programmed to deliver, add, aspirate or remove liquids to and from sample wells and assay chip wells at defined time intervals or in pre-determined conditions, and capable of automatically carrying out all sample preparation steps.
- Example 28A The kit of example 27 A, wherein the automated liquid handling robot comprises a custom-designed arm comprising an aspiration manifold connected to a vacuum line and configured for micro tip attachment.
- Example 29A The kit of example 28A, wherein the automated analyte detection and quantification system further comprises an automated imager.
- Example 30A The kit of example 29A, wherein the automated imager is integrated into the automated analyte detection and quantification system with direct liquid sampling and sample dilution capabilities.
- Example 31 A The kit of example 30A, wherein the automated imager is separate from the automated analyte detection and quantification system with direct liquid sampling and sample dilution capabilities.
- Example 32A The kit of example 30A, wherein the automatic imager comprises a fluorescence reader.
- Example 33A The kit of example 32A, wherein the custom software integrates and connects the liquid handling robot, the vacuum system, the voltage power supply and the automatic imager, are configured to be integrated and connected by a custom software.
- Example 34A The kit of example 33A, wherein the automated liquid handling robot is configured to deliver or aspirate one or more assay reagents to one or more wells in the consumable assay chips at different times or in different sequences.
- Example 35 A The kit of example 34A, wherein the automated system is configured to detect the presence of one or more analytes in a liquid sample and quantify detected amounts of one or more analytes within a period of time from about 10 minutes to about 4 hours.
- Example 36A The kit of example 35A, wherein the liquid sample is one or more of a biological sample, a cell suspension, supernatant or lysate, plant extracts, seawater, a microfilm fluid, water samples, or a beverage.
- the liquid sample is one or more of a biological sample, a cell suspension, supernatant or lysate, plant extracts, seawater, a microfilm fluid, water samples, or a beverage.
- Example 37A The kit of example 36A, wherein the biological sample is blood, serum, urine, or a body fluid from a human or animal.
- Example 38 A The kit of example 37 A, wherein the automated analyte detection and quantification system is configured to detect and quantify one or more of a protein, peptide, antibody, nucleic acid, biomarker, hormone, metabolite, carbohydrate and lipid.
- Example 39A The kit of example 38A, wherein detection comprises one or more of an immunoassay, nucleic acid test, multiplex diagnostic test, biomarker measurement or detection, and/or proteomic profiling.
- Example 40 A The kit of example 39A, wherein the automated system is configured to allow one or more liquid samples and one or more reagents to be separately and at different times introduced into the system.
- Example 41 A The kit of example 40A wherein the liquid sample volume is from about 0.2pL to about lOOOpL.
- Example 42 A The kit of example 41 A, wherein the automated analyte detection and quantification system is configured to apply directional electric field, such that one or more reagents are electrokinetically and sequentially transported from one well to another on the assay chips.
- Example 43 A The kit of example 42A, wherein the automated analyte detection and quantification system is configured to allow a liquid handling robot to precisely transfer, dispense into, deliver to or aspirate from different samples or one or more reagents at different times or in different cycles, in order to perform assays on target analytes.
- Example 44A The kit of example 43 A, wherein the assays comprise one or more of sandwich antibody detection, enzyme-labeled antigen reaction, fluorometric detection, in situ hybridization, microarray technology, affinity binding, radioactive and colorimetric binding.
- the assays comprise one or more of sandwich antibody detection, enzyme-labeled antigen reaction, fluorometric detection, in situ hybridization, microarray technology, affinity binding, radioactive and colorimetric binding.
- an automated analyte detection and quantification system with direct sampling capabilities, which automates detection and quantification workflows of macromolecules, such as proteins, peptides, antibodies, nucleic acid markers, hormones, metabolites, carbohydrates, lipids and other analytes of interest, including sample dilution, and provides complex sigmoidal plotting and curve fitting data from which the user can calculate target analyte concentrations, within 10 minutes to 4 hours time.
- macromolecules such as proteins, peptides, antibodies, nucleic acid markers, hormones, metabolites, carbohydrates, lipids and other analytes of interest, including sample dilution
- the automated analyte detection and quantification system with direct sampling capabilities is a system in which all steps are automated and pre-programmed, such that little to no manual intervention is required. In some embodiments, the automated analyte detection and quantification system with direct sampling capabilities is a system in which not all steps are automated and pre-programmed, such that some manual intervention may be required, such as, for example, to move the chip caddy from a first location to a second location. [0233] The automated analyte detection and quantification system is configured to integrate microscale liquid handling, biomolecular measurement assay and data readout, such that the user only controls the system via external computer or integrated touch screen.
- the disclosed system may be operated by a person with minimal lab training in an automated fashion.
- the disclosed automated analyte detection and quantification system performs multiplex analysis with high efficiency and with sub-pg/ml sensitivity, thus providing a solution to the aforementioned challenges.
- the disclosed system comprises an automated liquid handling robot and an assay subunit.
- the automated liquid handling robot is a custom-designed robot having microliter pipetting capabilities, and programmed to deliver, add, aspirate or remove liquids from sample wells at defined time intervals or in pre-determined conditions.
- the liquid handling robot is additionally configured to automatically carry out all necessary sample preparation steps before an assay, such as reagent mixing and sample dilution.
- the automated liquid handling robot comprises a custom-designed and manufactured arm comprising an aspiration manifold configured to be connected to a vacuum line.
- the size of the manifold may be varied to adjust for attachment of macrotips or microtips, such that the robot may deliver or aspirate reagents, buffers, or the like into sample wells as needed, with millimeter or sub-millimeter accuracy.
- the assay subunit is a system that comprises a conductive connector assembly comprising a lid and a printed circuit board (PCB) interface, an electrode assembly configured to fit into the connector assembly and to hold consumable assay chips, a vacuum pump, and a programmable voltage power supply connected to the connector interface.
- the electrode assembly houses a hinged precision electrode interface, which comprises multiple electrode rails. All components of the assay subunit can be installed in only one direction and self-align: the assay chips are placed into the electrode assembly, which fits under the connector assembly, which is then locked with fitting screws or a latch lock. Therefore, no training or expertise by the user is required.
- the system may further comprise an automated imager.
- the automated imager may be integrated into the system, or it may be a separate unit from the system.
- the automatic imager may comprise a fluorescence imaging reader equipped with features, such as a microscope, excitation channels, optical filters, a photon measurement system such as a camera or photomultiplier tube system, objective lenses, an autofocus system, auto exposure, light intensity active monitoring and regulation systems, and/or an automated image analysis and reporting system.
- the voltage power supply may comprise from one to ten independent outputs for single or multiple connections and it is configured to deliver a voltage from 0 to 5,000 volts.
- the software is configured to integrate and connect the liquid handling robot, the vacuum system, the voltage power supply and the imaging system, to enable image analysis and advanced data analysis.
- the connector assembly may be fixed to a plate at the automated liquid handling robot’s base, and it is configured to hold the electrode assembly and transmit electricity to the electrode rails within the electrode assembly, while providing space for liquid handling access to the assay chips.
- the electrode assembly comprises a bottom metal component housing a spring mechanism configured to align a chip caddy within the electrode assembly, and a top lid comprising an insulating electrode frame holding the electrode rails.
- the electrode rails are configured to be straight and aligned flat and parallel to the chip caddy, such that all electrodes are positioned properly at the edge of each well.
- the electrode assembly is configured to be in either an open or closed position, and it is configured to connect with the connector assembly.
- the electrode assembly can be washed, bleached, disinfected and reused as needed.
- the chip caddy contains the consumable assay chips. These consumable assay chips may be single use chips or reusable chips.
- the consumable assay chips are configured to contain wells designed to accept multiple samples and reagents for multiplex analyte detection and quantification.
- the caddy is compatible with most biological buffers and chemicals, such that the assay chips can be installed to the caddy and stored in wet conditions.
- the chip caddy may contain f or more assay chips.
- Each assay chip may contain 2 sample wells, and each chip caddy may contain f6 sample wells, 64 sample wells, 256 sample wells, 640 sample wells, f280 sample wells, 3200 sample wells, or 6400 sample wells.
- Each well has a diameter from about f mm to about 5 mm, or from about f .5 mm to about 3 mm.
- Two or more wells may be connected via channels to allow for electric field-guided migration of reagents.
- the channels may be cylindrical in shape, or other suitable shapes, such as D-shaped, square, oval, etc.
- the dimension of the channel may be for .5 micrometers to 1000 micrometers in width and/or depth.
- the length of the channels can be of any suitable lengths, for example from a few millimeters to a few centimeters.
- the automated liquid handling robot is configured to deliver or aspirate one or more assay reagents in appropriate sequence to one or more wells within the consumable chips. [0245] Once the connector assembly and the electrode assembly within the connector assembly are closed into the appropriate position, each electrode in the electrode rails is configured to sit on the edge of each well and to receive electricity through the connector assembly.
- Each electrode may have a thickness between 0.1 mm and 1 mm, or between 0.3 mm and 0.7 mm.
- each electrode is a laser-welded platinum electrode comprising an angled top to allow contact with the liquid in the wells and prevent collisions with the microtips delivering or aspirating liquids to or from the wells.
- the assay subunit is configured to hold the consumable chips in place and deliver and maintain electrical conductivity within all wells simultaneously with millimeter or sub millimeter spatial accuracy.
- the disclosed automated system is configured to detect the presence of one or more analytes of interest in a liquid sample and quantify detected amounts of one or more analytes within a period of time from about 10 minutes to about 4 hours.
- Liquid samples may include, but are not limited to, biological samples, such as blood, serum, and urine, cell suspensions, cell supernatants and lysates, plant extracts, sea water, microfilm fluids, running water, and beverages.
- Analytes may include, but are not limited to, proteins, peptides, antibodies, nucleic acids, biomarkers, hormones, metabolites, carbohydrates and lipids, or other macromolecules of interest.
- Suitable detection methods include, but are not limited to, immunoassays, nucleic acid tests, clinical diagnostics, biomarker detection, and proteomic profiling.
- the disclosed automated system is configured to allow one or more liquid samples and one or more reagents to be introduced separately and at different times into the system. Liquid samples may be in a volume amount from about 0.2pl to about IOOOmI.
- the disclosed automated system is configured to apply directional electric field to the assay chips, such that one or more reagents are electrokinetically and sequentially transported from one well to the other.
- the disclosed automated system is also configured to allow the liquid handling robot to precisely transfer, dispense into, deliver to or aspirate from different samples one or more reagents at different times or in different cycles, in order to carry out sample preparation steps, or capture and bind target analytes. Capturing and binding target analytes may include, without limitations, sandwich antibody detection, enzyme-labeled antigen reaction, fluorometric detection, in situ hybridization, microarray technology, affinity binding, radioactive and colorimetric binding.
- the disclosed automated methods comprise (a) separately introducing the liquid sample and one or more reagents into the disclosed automated analyte detection and quantification system with direct sampling capabilities; (b) choosing an assay protocol from a list of pre validated assay protocols to detect and quantify one or more target analytes; (c) closing the connector assembly and the electrode assembly within the connector assembly; (d) starting the automated system; (e) waiting 10 to 240 minutes; and (f) calculating target analyte concentrations from detection and quantification data presented by the automated system.
- the step of separately introducing the liquid samples and reagents into the automated analyte detection and quantification system may comprise automated dilution of the fluid samples and/or the reagents with a loading medium prior to delivery of each liquid sample and delivering each reagent into separate, inter-connected wells of the consumable assay chips by the automated liquid handling robot, and placing a chip caddy containing one or more consumable assay chips into the electrode assembly located below the connector assembly.
- Assay chip placement and electrode assembly may be automated and pre-programmed or performed manually.
- the system applies a voltage difference through the conductive pins in the connector assembly to the electrode rails within the electrode assembly to generate a directional electric field between the wells and transport reagent or analyte molecules from well- to-well.
- the disclosed automated methods may comprise several cycles of automated fluid delivery and/or aspiration by the liquid handling robot, followed by automated electric field application to move one or more reagent or analyte molecules from well-to-well.
- Analyte detection may include labeling the analyte of interest with a detectable label and detecting the signal emitted by the detectable label.
- Detectable labels include, but are not limited to, a fluorescent label, a colorimetric label, a chemo luminescent label, a color reagent, an enzyme-linked reagent, an antibody-linked reagent, a radiolabel or a magnetic label.
- Analyte quantification may include any quantitative analysis, such as advanced data analysis, display of results, composing reporting structures, validation of image- derived metrics with anatomic and physiological parameters, and the use of metrics in research, prevention, diagnosis, prognosis, and medical treatment.
- the system and methods disclosed herein provide accurate, rapid and effective detection and quantification of analytes in liquid samples.
- the goal of the study was to assess the variation of ILl Beta concentrations in immune response to various drug/treatment combinations applied to renal carcinoma cell cultures obtained from subjects in clinical trial.
- ILl Beta is an Interleukin 1 family cytokine that plays an important role in inflammatory response. It is involved in cell proliferation, differentiation and apoptosis and, because of its potential to modulate acute inflammation, ILIB is a biomarker of interest for therapeutic applications and drug development safety assessments. In renal cell carcinoma, ILIB is one of the major mediators of local and systemic inflammation.
- ILIB was measured for biomarker-assisted therapy.
- Primary tumor cells were removed via micro-biopsy from clinical trial patients undergoing treatment for renal cell carcinoma. The tumor cells were then incubated in vitro with combinations of therapeutics to determine response and impact on secreted protein biomarkers.
- the goal of this study was to preserve precious samples from the tumor cells and compare the efficacy of microvolume immunoassays to conventional technology.
- the available sample volume that was tested for each condition was 10 pi. Of the 10 m ⁇ sample, a 2.5 m ⁇ aliquot was diluted 4 times into the assay diluent. From the resulting 10 m ⁇ of total diluted sample, 2.5 m ⁇ were loaded into the sample wells. The remaining 7.5 m ⁇ of the original sample were preserved for future assays. The assay was completed in less than an hour from start to finish in a hands-free, fully automated manner. The data presented here were automatically calculated using analysis software.
- Step 1 The robot pipettor first picks up pipettes.
- Step 2 The robot pipettor performs sample dilutions (e.g., places about a 9 m ⁇ and places into tubes). Then the robot takes 1 m ⁇ from raw samples and mixes the raw samples with the 9 m ⁇ of the diluent. The robot pipettor would repeat this process for multiple samples.
- sample dilutions e.g., places about a 9 m ⁇ and places into tubes. Then the robot takes 1 m ⁇ from raw samples and mixes the raw samples with the 9 m ⁇ of the diluent. The robot pipettor would repeat this process for multiple samples.
- Step 3 The robot pipettor then pick up 2 m ⁇ of buffer and move to the assay chip location. Before dispensing the buffer, the robot aspirator clears up liquid from the waste wells of the chip assays. The robot pipettor then dispenses the buffer to one of the wells of the pair of wells.
- Step 4 The robot pipettor repeats the steps 1-3 but for sample fluids.
- the robot pipettor picks up and dispenses sample into samples into the samples wells. Before dispensing the sample into the sample wells, the robot aspirator clears up liquid from the sample wells of the chip assays of the chip caddy.
- Step 5. The robot pipettor then dispenses pipettor tips and parks into position. At this point, the samples and the buffer have been filled into the respect wells.
- Step 6 The electrode assembly is positioned into place causing the electrodes tips to be submerged into the respective pairs of waste and sample wells. A voltage is then applied for a set period of time thereby causing a current between the fluid in the pair of wells.
- Step 7 When the duration of applied voltage is completed, the robot pipettor repeat step 3. This may be done for example, three times to wash wells of the chip caddy.
- Step 8 Steps 4 through 5 may be repeated to add new samples to the washed wells, and then the voltage in step 6.
- Step 9 After the samples processing is done, an imager obtains images of all of the location of the pairs of wells of the chip caddy (for example, 96 locations).
- the digital imagery may be in two spectrums. One primary image (to show exposure), and a second image to show three to nine different time exposures (e.g, 20ms, 400ms, 800ms, 1600ms, 3200ms.)
- Step 10 The images are then transferred to a computer where software performs an analysis and generates data pertaining to the processed samples.
- the robotic system may perform the steps of: Step 1.
- the robotic pipettor picks up pipette tips.
- Step 2. The robotic pipettor picks up liquid.
- Step 3. A vacuum manifold is used to extract fluid and clean the wells.
- Step 4. The robotic pipettor dispenses to the cleaned wells.
- Step 5. The robotic pipettor discards the pipettes.
- the robotic system performs multiple steps.
- Step 1 The robotic system performs an operation to dilute samples.
- Step 2. The robotic system provides a buffer refresh to all wells of an assay chip.
- Step 3 The robotic system then transfers samples to wells of the assay chip.
- Step 4 The robotic system then applies a predetermined voltage the electrode rails of the assembly to transport sample into the channel interconnecting the pairs of wells.
- Step 5 The robotic system washes the wells multiple times.
- Step 6 The robotic system then applies a predetermined voltage to electrode rails of the electrode assembly to remove nonspecific samples from the channel.
- Step 7 The robotic system washes the wells multiple times.
- Step 8 The robotic system transfers primary antibody to the wells.
- Step 9 The robotic system then applies a predetermined voltage to the electrode rails of the electrode assembly to transport primary antibodies into the channels.
- Step 10 The robotic system then washes the wells multiple times.
- Step 11 The robotic system then applies a predetermined voltage to the electrode rails of the electrode assembly to remove unbound primary antibodies from the channels.
- Step. 12 The robotic system then washes the wells multiple times.
- Step 13 the robotic system then repeats steps 8-12 as needed. For example, if using a secondary antibody, steps 8-12 may be repeated.
- Step 14 Obtain images of all of the location of the pairs of wells of the chip caddy, and analyzing the image to generate data.
- Example IB An automated analyte detection and quantification system with direct sampling capabilities, wherein the automated analyte detection and quantification system comprises a custom-designed automated liquid handling robot having microliter pipetting capabilities and programmed to deliver, add, aspirate or remove liquids to and from sample wells at defined time intervals or in predetermined conditions, and an assay subunit system comprising a conductive connector assembly, an electrode assembly, a vacuum pump, and a programmable voltage power supply.
- Example 2B The automated analyte detection and quantification system of Example IB, wherein the automated liquid handling robot comprises a custom-designed and manufactured arm comprising an aspiration manifold connected to a vacuum line and configured for micro tip attachment.
- Example 3B The automated analyte detection and quantification system of Example 2B, wherein the connector assembly comprises a lid and a printed circuit board (PCB) interface.
- PCB printed circuit board
- Example 4B The automated analyte detection and quantification system of Example 3B, wherein the connector assembly is fixed to a plate at the automated liquid handling robot’s base.
- Example 5B The automated analyte detection and quantification system of Example 4B, wherein the electrode assembly is configured to fit into the connector assembly and to hold consumable assay chips, and wherein the electrode assembly comprises a hinged precision electrode interface.
- Example 6B The automated analyte detection and quantification system of Example 5B, wherein the hinged precision electrode interface comprises multiple electrode rails.
- Example 7B The automated analyte detection and quantification system of Example 6B, wherein the connector assembly is configured to transmit electricity to the electrode rails within the electrode assembly.
- Example 8B The automated analyte detection and quantification system of Example 7B, wherein the electrode assembly comprises a bottom component housing a spring mechanism configured to align a chip caddy within the electrode assembly, and a top lid comprising an insulating electrode frame holding the electrode rails.
- Example 9B The automated analyte detection and quantification system of Example 8B, wherein the electrode rails are configured to be straight and aligned flat and parallel to the chip caddy.
- Example 10B The automated analyte detection and quantification system of Example 9B, wherein the electrode assembly is configured to be in open or closed position.
- Example 11B The automated analyte detection and quantification system of Example 10B, wherein the electrode assembly is removable from the connector assembly.
- Example 12B The automated analyte detection and quantification system of Example 11B, wherein the electrode assembly is configured to be washed, bleached, disinfected and reused.
- Example 13B The automated analyte detection and quantification system of Example 12B, wherein the chip caddy contains consumable assay chips.
- Example 14B The automated analyte detection and quantification system of Example 13B, wherein the consumable assay chips are single use chips.
- Example 15B The automated analyte detection and quantification system of Example 13B, wherein the consumable assay chips are reusable chips containing wells designed to accept multiple samples and carry out analyte measurement assays on multiple samples simultaneously.
- Example 16B The automated analyte detection and quantification system of Example 13B, wherein the chip caddy contains 1 or more, 4 or more, 10 or more, 20 or more, 50 or more, or 100 or more consumable assay chips.
- Example 17B The automated analyte detection and quantification system of Example 16B, wherein each assay chip contains 2 sample wells, 16 sample wells, 64 sample wells, 256 sample wells, 640 sample wells, 1280 sample wells, 3200 sample wells, or 6400 sample wells.
- Example 18B The automated analyte detection and quantification system of Example 17B, wherein each well has a diameter from about 1 mm to about 5 mm, or from about 1.5 mm to about 3 mm, and wherein two or more wells are interconnected via channels.
- Example 19B The automated analyte detection and quantification system of Example 5B, wherein the voltage power supply is connected to the electrode interface, and wherein the voltage power supply comprises from 1 to 10 independent outputs.
- Example 20B The automated analyte detection and quantification system of Example IB, wherein the electrode assembly further comprises an automated imager.
- Example 21B The automated analyte detection and quantification system of Example 20B, wherein the automated imager is integrated into the system.
- Example 22B The automated analyte detection and quantification system of Example 20B, wherein the automated imager is separate from the system.
- Example 23B The automated analyte detection and quantification system of Example 20B, wherein the automatic imager comprises a fluorescence reader.
- Example 24B The automated analyte detection and quantification system of Example 23B, wherein the software is configured to integrate and connect the liquid handling robot, the vacuum system, the voltage power supply and the automatic imager.
- Example 25B The automated analyte detection and quantification system of Example 24B, wherein, when the connector assembly and the electrode assembly underneath the connector assembly are in closed position, each electrode in the electrode rails is configured to sit on the edge of each well and to receive electricity through the connector assembly.
- Example 26B The automated analyte detection and quantification system of Example 25B, wherein each electrode has a thickness between 0.1 mm and 1 mm, or between 0.3 mm and 0.7 mm.
- Example 27B The automated analyte detection and quantification system of Example 26B, wherein each electrode is a laser-welded platinum electrode comprising an angled top.
- Example 28B The automated analyte detection and quantification system of Example 27B, wherein the electrode assembly is configured to hold the consumable assay chips in place and maintain electrical conductivity within the wells in the assay chips.
- Example 29B The automated analyte detection and quantification system of Example 28B, wherein the automated liquid handling robot is configured to deliver or aspirate one or more assay reagents to and from one or more wells in the consumable assay chips at different times or in different sequence.
- Example 30B The automated analyte detection and quantification system of Example IB, wherein the automated system is configured to detect the presence of one or more analytes in a liquid sample and quantify detected amounts of one or more analytes within a period of time from about 10 minutes to about 4 hours.
- Example 3 IB The automated analyte detection and quantification system of Example 30, wherein the liquid sample is one or more of a biological sample, a cell suspension, supernatant or lysate, plant extracts, seawater, a microfilm fluid, water samples, or a beverage.
- Example 32B The automated analyte detection and quantification system of Example 3 IB, wherein the biological sample is blood, serum, urine, or a body fluid from a human or an animal.
- Example 33B The automated analyte detection and quantification system of Example 32B, wherein the automated system is configured to detect and quantify one or more of a protein, peptide, antibody, nucleic acid, biomarker, hormone, metabolite, carbohydrate and lipid.
- Example 34B The automated analyte detection and quantification system of Example 33B, wherein detection comprises one or more of an immunoassay, nucleic acid test, multiplex diagnostic test, biomarker measurement or detection, and/or proteomic profiling.
- Example 35B The automated analyte detection and quantification system of Example IB, wherein the automated system is configured to allow one or more liquid samples and one or more reagents to be separately and at different times introduced into the system.
- Example 36B The automated analyte detection and quantification system of Example 35B, wherein the liquid sample volume is from about 0.2pl to about IOOOmI.
- Example 37B The automated analyte detection and quantification system of Example 36B, wherein the automated system is configured to detect and quantify one or more analytes in a period of time from about 10 minutes to about 4 hours.
- Example 38B The automated analyte detection and quantification system of Example 37B, wherein the automated system is configured to apply directional electric field.
- Example 39B The automated analyte detection and quantification system of Example 38B, wherein the automated system is configured to allow a liquid handling robot to precisely transfer, dispense into, deliver to or aspirate from different samples one or more reagents at different times or in different cycles, in order to capture and bind target analytes.
- Example 40B The automated analyte detection and quantification system of Example 39B, wherein capturing and binding target analytes comprise one or more of sandwich antibody detection, enzyme-labeled antigen reaction, fluorometric detection, in situ hybridization, microarray technology, affinity binding, radioactive and colorimetric binding.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Physics & Mathematics (AREA)
- Clinical Laboratory Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Robotics (AREA)
- Hematology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Automatic Analysis And Handling Materials Therefor (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Provided herein are a system, kit and methods that allow quick and precise detection, identification and quantification of analytes in liquid samples. The kit may be used in automated and pre-programmed singleplexed and multiplexed detection and quantification of one or more analytes in a liquid samples. The kit may include a chip caddy, consumable assay chips, an electrode assembly, an electrical connector assembly, one or more cables, a voltage supply, a vacuum pump, a vacuum trap, custom-designed manifolds, one or more buffers, reagents and instructions for use.
Description
AUTOMATED ANALYTE MEASUREMENT SYSTEMS AND KITS FOR USE
THEREWITH
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 62/965,725, filed January 24, 2020, which is hereby incorporated by reference in its entirety.
[0002] This application claims the benefit of U.S. Provisional Application No. 62/965,729, filed January 24, 2020, which is hereby incorporated by reference in its entirety.
FIELD OF THE INVENTION
[0003] The present invention relates to kits for quick and precise detection, identification and quantification of small molecules and macromolecules, such as proteins, peptides, antibodies, nucleic acid markers, hormones, metabolites, carbohydrates, lipids and other analytes of interest, in liquid samples. The disclosed kits may be used for research, clinical applications, diagnosis and treatment.
[0004] The present invention also relates to a system for quick and precise detection, identification and quantification of small molecules and macromolecules, such as proteins, peptides, antibodies, nucleic acid markers, hormones, metabolites, carbohydrates, lipids and other analytes of interest, in liquid samples, and to methods of analyte detection and quantification that comprise the use of the disclosed system. The disclosed system may be used for research, clinical applications, and for diagnosis and treatment purposes.
BACKGROUND
[0005] Early detection and quantification of protein biomarkers are crucial for treatment and prevention strategies. While commercially available immunoassay techniques for protein detection and quantification are reasonably inexpensive, they suffer from considerable drawbacks.
[0006] In particular, most commercially available tests require the use of one or more antibodies with high specificity and sensitivity for a particular protein at a time and many of these tests are not always suitable to perform multiplexed detection. Thus, multiple assays often need to be performed on each sample if multiplexed protein analysis is desired. In addition, most immunoassays are laborious and time-consuming, have multiple steps, and require hands-on user intervention.
[0007] Several approaches have been attempted to make immunoassays faster and user- friendly. However, these techniques still require several hours of time and relatively large volumes of liquid samples. Therefore, immunoassays often constitute an impediment to producing high quality real time quantitative protein measurement data within the life science disciplines. This is especially true when limited biosample quantities are available.
[0008] There is a need for an accurate and reliable system, kits and methods that quickly and reliably detect and quantify proteins and other analytes for research and for diagnosis and preventive and therapeutic guidance. The present application presents a solution to the aforementioned challenges by providing kit components that can be fit into various automated liquid handling systems, and provide rapid and highly efficient measurements of macromolecules.
SUMMARY
[0009] Summary Regarding Kit used with Automated System
[0010] Disclosed herein are kit components that fit into automated liquid handling systems and provide rapid and highly efficient multiplex detection and quantification of small molecules and macromolecules, such as proteins, peptides, antibodies, nucleic acids, biomarkers, hormones, metabolites, carbohydrates and lipids of interest, in liquid samples. The disclosed kits may be used on microquantities of liquid samples for a large number of tests, such as immunoassays, nucleic
acid tests, clinical diagnostics, biomarker detection, and proteomic profiling, with no or limited manual interventions from the user.
[0011] Thus, provided herein are kits for automated and pre-programmed singleplex and multiplex analyte detection and quantification from liquid samples.
[0012] In some embodiments, the disclosed kits may include one or more of a chip caddy, consumable assay chips, an electrode assembly, a connector assembly comprising a lid and a printed circuit board (PCB) interface, cables, a voltage power supply, a vacuum pump, a vacuum trap, and custom-designed fluid delivery and aspiration manifolds fitting different size liquid handling robot arms, and may further comprise one or more buffers, reagents and instructions for use.
[0013] The disclosed components of the kits provided herein are configured to fit into different automated systems for singleplex or multiplex detection and quantification of macromolecules, and to be connected to different types of automated imagers. Moreover, the disclosed components of the kits provided herein are configured to be used for a large number of tests, such as immunoassays, nucleic acid tests, multiplexed protein measurements, clinical diagnostics, biomarker detection, and proteomic profiling, for the detection and quantification of proteins, nucleic acids, biomarkers, hormones, metabolites, carbohydrates and lipids of interest, in liquid samples. Liquid samples may vary in volume from about 0.2 pi to about IOOOmI.
[0014] The disclosed components of the kits provided herein are configured to connect to different types of automated imagers. Suitable automated imagers may comprise a LED or laser- induced fluorescence imaging reader equipped with fluorescence excitation sources, optical filters, a photon measurement system (such as a camera or a photomultiplier tube system), objective
lenses, exposure and light intensity active monitoring and regulation systems, and automated image analysis and reporting systems.
[0015] In some embodiments, the assay chips are microfluidic chips that comprise glass or one or more polymers. In some embodiments the assay chips are functionalized printed circuit boards (PCBs). In some embodiments, the assay chips are paper-based and comprise cellulosic materials such as organic fibers.
[0016] In some embodiments, the chip caddy in the disclosed kits is configured to contain assay chips. In some embodiments, the consumable assay chips are single use chips. In some embodiments, the consumable assay chips are reusable chips. In some embodiments, the assay chips are configured to comprise wells designed to accept multiple samples and reagents for multiplex analyte detection and quantification.
[0017] In some embodiments, the chip caddy comprises one or more metals, such as aluminum, a polymer, or any mixture thereof. In some embodiments, the chip caddy in the disclosed kits is configured to contain 1 or more chips. In some embodiments, each chip contains 2 sample wells. In some embodiments, each chip caddy contains 16 sample wells, 64 sample wells, 256 sample wells, 640 sample wells, 1280 sample wells, 3200 sample wells, or 6400 sample wells. In some embodiments, each well has a diameter from about 1 mm to about 5 mm, or from about 1.5 mm to about 3 mm. In some embodiments, two or more wells are connected via channels.
[0018] In some embodiments, the electrode assembly is configured to fit into the connector assembly and to hold consumable assay chips. In some embodiments, the electrode assembly is configured to comprise a hinged precision electrode interface connectable to the programmable voltage power supply. The voltage power supply may comprise from one to ten independent outputs.
[0019] In some embodiments, the electrode assembly is configured to comprise a bottom component housing a spring mechanism configured to align a chip caddy within the electrode assembly and a top lid comprising an insulating electrode frame holding electrode rails. In some embodiments, the electrode rails are configured to be straight and aligned flat and parallel to the chip caddy. In some embodiments, the electrode assembly is configured to be in open or closed position. In some embodiments, the electrode assembly is configured to be removable from the connector assembly. In some embodiments, the electrode assembly can be washed, bleached and disinfected and used for additional tests.
[0020] In some embodiments, the connector assembly is configured to be attachable to an automated liquid handling robot’s base. In some embodiments, the connector assembly is configured to transmit electricity to the electrode rails within the electrode assembly.
[0021] In some embodiments, when the connector assembly and the electrode assembly within the connector assembly are in closed position, each electrode in the electrode rails is configured to sit on the edge of each well and to receive electricity through the connector assembly. In some embodiments, each electrode has a thickness between 0.1 mm and 1 mm, or between 0.3 mm and 0.7 mm. In some embodiments, each electrode is a laser-welded platinum electrode comprising an angled top.
[0022] In some embodiments, the vacuum pump and the vacuum trap are configured to be connectable to a programmable voltage power supply. The voltage power supply may comprise from one to ten independent outputs.
[0023] In some embodiments, the software is configured to integrate and connect the liquid handling robot, the vacuum system, and the voltage power supply to fully automate the assay running steps and enable advanced data analysis.
[0024] In some embodiments, the software is configured to integrate and connect the liquid handling robot, the vacuum system, the voltage power supply and the imaging system, to fully automate the assay running steps and readout, and enable image analysis and advanced data analysis.
[0025] In some embodiments, the custom-designed fluid delivery and aspiration manifolds in the disclosed kits are configured to be connectable to a vacuum line and for macro tip or micro tip attachment.
[0026] In some embodiments, the disclosed components of the kits provided herein are configured to hold the consumable chips in place and maintain electrical conductivity within the wells in the chips. In some embodiments, the automated liquid handling robot is configured to deliver or aspirate one or more assay reagents in appropriate sequence to one or more wells in the consumable chips.
[0027] In some embodiments, the disclosed kit components are configured to fit into an automated analyte detection and quantification system with direct sampling capabilities. The disclosed system comprises an automated liquid handling robot and an assay subunit.
[0028] In some embodiments, the automated liquid handling robot is a custom-designed robot having microliter pipetting capabilities, and programmed to deliver, add, aspirate or remove liquids from sample wells at defined time intervals or in pre-determined conditions. In some embodiments the liquid handling robot is capable of automatically carrying out all necessary sample preparation steps before an assay, such as reagent mixing and sample dilutions.
[0029] In some embodiments, the automated liquid handling robot comprises a custom- designed arm comprising an aspiration manifold connected to a vacuum line and configured for micro tip attachment.
[0030] In some embodiments, the system comprises the connector assembly, the electrode assembly configured to fit in the connector assembly and to hold consumable assay chips, and comprising a hinged precision electrode interface, the vacuum pump, and the programmable voltage power supply comprising one to ten independent outputs connected to the electrode interface.
[0031] In some embodiments, an automated imager is integrated with the system. In some embodiments, the automated imager is separate from the system. In some embodiments, the automatic imager comprises a LED or laser-induced fluorescence imaging reader equipped with fluorescence excitation channels, optical filters, a photon measurement system, such as camera or a photomultiplier tube system, objective lenses, systems for autofocus, auto-exposure, light intensity monitoring and regulation, and automated image analysis and reporting systems.
[0032] In some embodiments, the software integrates and connects the liquid handling robot, the vacuum system, the voltage power supply and the imaging system, to enable image analysis and advanced data analysis.
[0033] In some embodiments, the automated liquid handling robot is configured to deliver or aspirate one or more assay reagents in appropriate sequence to one or more wells in the consumable chips.
[0034] In some embodiments, the disclosed automated system is configured to detect the presence of one or more analytes of interest in a liquid sample and quantify detected amounts of one or more analytes within a period of time from about 10 minutes to about 4 hours. Liquid samples may include, but are not limited to, biological samples, such as blood, serum, and urine, cell suspensions, cell supernatants and lysates, plant extracts, sea water, microfilm fluids, running water, and beverages.
[0035] In some embodiments, the disclosed automated system is configured to detect and quantify macromolecules, such as proteins, peptides, antibodies, nucleic acids, biomarkers, hormones, metabolites, carbohydrates and lipids of interest, from liquid samples. Suitable detection methods include, but are not limited to, immunoassays, nucleic acid tests, clinical diagnostics, biomarker detection, and proteomic profiling.
[0036] In some embodiments, the disclosed automated system is configured to allow one or more liquid samples and one or more reagents to be introduced separately and at different times into the system. The disclosed automated system is configured to detect and quantify one or more analytes in liquid samples that are in an amount from about 0.2pl sample to about IOOOmI sample. Additionally, the disclosed automated system is configured to detect and quantify one or more analytes within a period of time, such as from about 10 minutes to about 4 hours.
[0037] The disclosed automated system is configured to apply directional electric field to the assay chips, such that one or more reagents are electrokinetically and sequentially transported from one well to the other. The disclosed automated system is also configured to allow the liquid handling robot to precisely transfer, dispense into, deliver to or aspirate from different samples one or more reagents at different times or in different cycles, in order to carry out sample preparation steps, or capture and bind target analytes. In some embodiments, capturing and binding target analytes may include, but are not limited to, sandwich antibody detection, enzyme-labeled antigen reaction, fluorometric detection, in situ hybridization, microarray technology, affinity binding, radioactive and colorimetric binding.
[0038] Summary Regarding Automated System
[0039] Also, disclosed herein are an automated system and automated methods for rapid and highly efficient multiplex detection and quantification of small molecules and
macromolecules, such as proteins, peptides, antibodies, nucleic acids, biomarkers, hormones, metabolites, carbohydrates and lipids of interest, from liquid samples. The disclosed automated system and methods may be used on microquantities of liquid samples for a large number of tests, such as immunoassays, nucleic acid tests, multiplex diagnostics, biomarker detection, and proteomic profiling, with no or limited manual interventions from the user.
[0040] Thus, in one embodiment, provided herein is an automated analyte detection and quantification system with direct sampling capabilities. The disclosed system comprises an automated liquid handling robot and an assay subunit.
[0041] In some embodiments, the automated liquid handling robot is a custom-designed robot having microliter pipetting capabilities, and programmed to deliver, add, aspirate or remove liquids to and from sample wells at defined time intervals or in pre-determined conditions.
[0042] In some embodiments, the automated liquid handling robot comprises a custom- designed and manufactured arm comprising an aspiration manifold connected to a vacuum line and configured for micro tip attachment.
[0043] In some embodiments, the assay subunit is a system that comprises a connector assembly comprising a lid and a printed circuit board (PCB) interface with conductive pins, an electrode assembly configured to fit into the connector assembly and to hold consumable assay chips, and comprising a hinged precision electrode interface, a vacuum pump, and a programmable, software-controlled voltage power supply connected to the electrode interface comprising from one to ten independent outputs.
[0044] In some embodiments, an automated imager is integrated into the system. In some embodiments, the automated imager is separate from the system. In some embodiments, the automatic imager comprises a LED or laser-induced fluorescence imaging reader, which may be
equipped with a microscope, fluorescence excitation channels, optical filters, a photon measurement system, objective lenses, systems for autofocus, auto exposure, light intensity active monitoring and regulation, and an automated image analysis and reporting system.
[0045] In some embodiments, the software is configured to integrate and connect the liquid handling robot, the vacuum system, the voltage power supply and the imaging system, to enable image analysis and advanced data analysis.
[0046] In some embodiments, the connector assembly is fixed to a plate at the automated liquid handling robot’s base. In some embodiments, the hinged precision electrode interface comprises multiple electrode rails. In some embodiments, the connector assembly is configured to transmit electricity to the electrode rails within the electrode assembly.
[0047] In some embodiments, the electrode assembly comprises a bottom component housing a spring mechanism configured to align a chip caddy within the electrode assembly, and a top lid comprising an insulating electrode frame holding the electrode rails. In some embodiments, the electrode rails are configured to be straight and aligned flat and parallel to the chip caddy. In some embodiments, the electrode assembly is configured to be in either an open or closed position. In some embodiments, the electrode assembly is removable from the connector assembly. In some embodiments, the electrode assembly can be washed, bleached, disinfected and reused.
[0048] In some embodiments, the assay chips are microfluidic chips comprising glass or one or more polymers. In some embodiments the assay chips comprise functionalized microcapillaries composed of glass and/or polymer. In some embodiments the assay chips are functionalized printed circuit boards (PCBs). In some embodiments, the assay chips are paper- based devices comprising cellulosic materials, such as organic fibers.
[0049] In some embodiments, the consumable assay chips are contained in a chip caddy. In some embodiments, the consumable assay chips are single use chips. In some embodiments, the consumable assay chips are reusable chips. The consumable assay chips contain wells designed to accept multiple samples and reagents for multiplex analyte detection and quantification.
[0050] In some embodiments, the chip caddy comprises one or more metals, such as aluminum, one or more polymers such as plastic, or any mixture thereof. In some embodiments, the chip caddy contains 1 or more microfluidic chips or assay chips. In some embodiments, each chip contains 2 sample wells. In some embodiments, each chip caddy contains 16 sample wells, 64 sample wells, 256 sample wells, 640 sample wells, 1280 sample wells, 3200 sample wells, or 6400 sample wells. In some embodiments, each well has a diameter from about 1 mm to about 5 mm, or from about 1.5 mm to about 3 mm. In some embodiments, two or more wells are connected by channels.
[0051] In some embodiments, when the connector assembly and the electrode assembly within the connector assembly are in closed positions, each electrode in the electrode rails is configured to sit on the edge of each well and to receive electricity through the connector assembly. In some embodiments, each electrode has a thickness between 0.1 mm and 1 mm, or between 0.3 mm and 0.7 mm. In some embodiments, each electrode is a laser-welded platinum electrode comprising an angled top.
[0052] In some embodiments, the assay subunit is configured to hold the consumable chips in place and maintain electrical conductivity within the wells in the chips. In some embodiments, the automated liquid handling robot is configured to deliver or aspirate one or more assay reagents in appropriate sequence to one or more wells in the consumable chips.
[0053] In some embodiments, the disclosed automated system is configured to detect the presence of one or more analytes of interest in a liquid sample and quantify detected amounts of one or more analytes within a period of time from about 10 minutes to about 4 hours. Liquid samples may include, but are not limited to, biological samples, such as blood, serum, and urine, cell suspensions, cell supernatants and lysates, plant extracts, sea water, microfilm fluids, running water, and beverages.
[0054] In some embodiments, the disclosed automated system is configured to detect and quantify macromolecules, such as proteins, peptides, antibodies, nucleic acids, biomarkers, hormones, metabolites, carbohydrates and lipids of interest, from liquid samples. Suitable detection methods include, but are not limited to, immunoassays, nucleic acid tests, multiplex diagnostics, biomarker detection, and proteomic profiling.
[0055] In some embodiments, the disclosed automated system is configured to allow one or more liquid samples and one or more reagents to be introduced separately and at different times into the system. The disclosed automated system is configured to detect and quantify one or more analytes in liquid samples that are in a volume amount from about 0.2pl to about IOOOmI.
[0056] The disclosed automated system is configured to apply directional electric field to the electrode assembly, such that one or more reagents are electrokinetically and sequentially transported through the system to the one or more samples. The disclosed automated system is also configured to allow the liquid handling robot to precisely transfer, dispense into, deliver to or aspirate from different samples one or more reagents at different times or in different cycles, in order to capture and bind target analytes. In some embodiments, capturing and binding target analytes may include, but are not limited to, sandwich antibody detection, enzyme-labeled antigen
reaction, fluorometric detection, in situ hybridization, microarray technology, affinity binding, radioactive and colorimetric binding.
[0057] Also provided herein are automated methods for singleplex and multiplex detection and quantification of one or more analytes in a liquid sample, which require minimal or no manual interventions. The disclosed automated methods comprise (a) separately introducing the liquid sample and one or more reagents into an automated analyte detection and quantification system with direct sampling capabilities as described above; (b) choosing an assay protocol from a list of pre-validated assay protocols to detect and quantify one or more target analytes; (c) closing the connector assembly and the electrode assembly underneath the connector assembly; (d) starting the automated system; (e) waiting 10 to 240 minutes; and (f) calculating target analyte concentrations from detection and quantification data presented by the automated system.
[0058] The foregoing and other features of the disclosure will become more apparent from the following detailed description of several embodiments, which proceeds with reference to the accompanying figures.
[0059] The foregoing and other features of the disclosure will become more apparent from the following detailed description of several embodiments, which proceeds with reference to the accompanying figures.
BRIEF DESCRIPTION OF THE DRAWINGS
[0060] The present disclosure will become better understood from the detailed description and the drawings, wherein:
[0061] FIG. 1 A illustrates a diagram showing an example liquid handling robot.
[0062] FIG. IB illustrates a diagram showing control of system components.
[0063] FIGS. 2Aand 2B illustrate diagrams showing delivery of consumables into sample wells.
[0064] FIGS. 3A, 3B and 3C illustrates examples of four assay chips in a caddy.
[0065] FIGS. 4A and 4B illustrate a diagram showing a close-up view of the electrodes an electrode assembly.
[0066] FIGS. 5A, 5B, 5C and 5D illustrate diagrams showing assemblies in an open position.
[0067] FIGS. 6A and 6B illustrate diagrams showing assembly with conductive pins.
[0068] FIG. 7. illustrates a diagram showing an example vacuum arm designed to fit the liquid handling robot.
[0069] FIGS. 8A and 8B illustrate diagrams showing the connector assembly in the open position.
[0070] FIGS. 9A, 9B and 9C illustrate diagrams showing examples of the connector assembly in modes of operation.
[0071] FIGS. 10A, 10B illustrate diagrams showing the electrode assembly in modes of operation
[0072] FIG. IOC illustrates a diagram showing the chip caddy in a mode of operation.
[0073] FIG. 11 A - 1 ID illustrate diagrams showing the electrode frame and electrode rails in the electrode assembly.
[0074] FIGS. 12A, 12B and 12C illustrate diagrams showing views of the electrode frame and electrode rail placement.
[0075] FIGS. 13 A and 13B illustrate diagrams showing placement of electrode tips and electrode rail placement.
[0076] FIG. 14 illustrates a diagram showing a detailed view of the electrode and pipette tip placement.
[0077] FIG. 15 illustrates a diagram showing a standard curve for the human IL-1 Beta assay.
[0078] FIG. 16 illustrates a flowchart of a method for an automated method for singleplex and multiplex detection and quantification of one or more analytes in a liquid sample.
[0079] FIG. 17 illustrates a flowchart of a method for an automated method for singleplex and multiplex detection and quantification of one or more analytes in a liquid sample.
DETAILED DESCRIPTION
[0080] The following explanations of terms and methods are provided to better describe the present disclosure and to guide those of ordinary skill in the art in the practice of the present disclosure. As used herein, “comprising” means “including” and the singular forms “a” or “an” or “the” include plural references unless the context clearly dictates otherwise. For example, reference to “comprising a therapeutic agent” includes one or a plurality of such therapeutic agents. The term “or” refers to a single element of stated alternative elements or a combination of two or more elements, unless the context clearly indicates otherwise. For example, the phrase “A or B” refers to A, B, or a combination of both A and B. Furthermore, the various elements, features and steps discussed herein, as well as other known equivalents for each such element, feature or step, can be mixed and matched by one of ordinary skill in this art to perform methods in accordance with principles described herein. Among the various elements, features, and steps some will be specifically included and others specifically excluded in particular examples.
[0081] Unless explained otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this disclosure
belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. The materials, methods, and examples are illustrative only and not intended to be limiting. All references cited herein are incorporated by reference in their entirety.
[0082] In some examples, the numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth, used to describe and claim certain embodiments are to be understood as being modified in some instances by the term "about" or "approximately." For example, "about" or "approximately" can indicate +/- 20% variation of the value it describes. Accordingly, in some embodiments, the numerical parameters set forth herein are approximations that can vary depending upon the desired properties for a particular embodiment. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of some examples are approximations, the numerical values set forth in the specific examples are reported as precisely as practicable. The recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range.
[0083] To facilitate review of the various embodiments of this disclosure, the following explanations of specific terms are provided:
[0084] Administer or Apply: To provide or give a subject a composition, such as a pharmaceutical composition, by an effective route. Exemplary routes of administration include, but are not limited to, parenteral, topical, transdermal, oral, intravenous, and muscular routes.
[0085] Analog: A compound having a structure similar to another, but differing from it, for example, in one or more atoms, functional groups, or substructure.
[0086] Anesthetic agent: An active agent that causes reduction or loss of sensation.
[0087] Antagonist: A molecule that, upon binding to a cell receptor, competes and/or interferes with one or more ligands binding the same receptor, and thus reduces or prevents a response elicited by those ligands.
[0088] Antibiotic: A chemical substance capable of treating bacterial infections by inhibiting the growth of, or by destroying existing colonies of bacteria and other microorganisms.
[0089] Antibody: An immunoglobulin capable of specifically binding a target molecule, such as a carbohydrate, a polynucleotide, a lipid, or a polypeptide, via one or more antigen recognition sites, located in the variable region of the immunoglobulin molecule. The term “antibody” includes polyclonal and monoclonal antibodies, fragments thereof, such as Fab, Fab', F(ab')2 and Fv, single chain variable fragments (ScFv), mutants thereof, fusion proteins comprising an antibody portion, and any other modified configuration of the immunoglobulin molecule that comprises an antigen recognition site. Antibodies can be distinguished into five major classes, IgA, IgD, IgE, IgG, and IgM, according to the amino acid sequence of the constant domain in their heavy chains. Monoclonal antibodies are obtained from a substantially homogeneous population of antibodies, and specifically target a single epitope (determinant) of an antigen. Polyclonal antibodies target different epitopes on the antigen. The heavy and light chains of an antibody each comprise a variable region and a constant region. The variable regions of the heavy and light chain each consist of four framework regions (FR) connected by three complementarity determining regions (CDRs), also known as hypervariable regions. The CDRs in each chain are held together in close proximity by the FRs and form the antibody’s antigen-binding site. The constant regions of the heavy and light chains of an antibody provide structural stability and are not involved in antigen binding.
[0090] Antibody-drug conjugate (ADC): Complex molecules composed of an antibody linked to a biologically active cytotoxic payload or drug. By combining the targeting capabilities of monoclonal antibodies with the cancer-killing ability of cytotoxic drugs, antibody- drug conjugates allow for discrimination between healthy and diseased tissue. Unlike traditional chemotherapeutic drugs, antibody-drug conjugates target only cancer cells so that healthy cells are less severely affected.
[0091] Anti-Fungal Agent: An active agent capable of inhibiting the growth of or destroying fungi.
[0092] Anti-inflammatory agent: An active agent that reduces inflammation and swelling.
[0093] Anti-Oxidant: An active agent that inhibits oxidation or reactions promoted by oxygen or peroxides.
[0094] Anti-Protozoal Agent: An active agent capable of inhibiting the growth of or destroying protozoa microorganisms.
[0095] Anti- Viral Agent: An active agent that inhibits the replication of or destroys viruses.
[0096] Cancer: A condition characterized by unregulated cell growth. Examples of cancer include, but are not limited to, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, gastrointestinal cancer, Hodgkin's and non-Hodgkin's lymphoma, pancreatic cancer, glioblastoma, cervical cancer, glioma, ovarian cancer, liver cancer such as hepatic carcinoma and hepatoma, bladder cancer, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney cancer such as renal cell carcinoma and Wilms' tumors, basal cell carcinoma,
melanoma, prostate cancer, thyroid cancer, testicular cancer, esophageal cancer, and various types of head and neck cancer.
[0097] Chemotherapeutic agent or Chemotherapy: A chemical agent with therapeutic usefulness in the treatment of diseases characterized by abnormal cell growth. Such diseases include tumors, neoplasms, and cancer. In one example, a chemotherapeutic agent is a radioactive compound. In one example, a chemotherapeutic agent is a biologic, such as a monoclonal antibody. In some examples, a subject treated with an active agent using the disclosed methods, is, will be, or was previously treated with chemotherapy. Exemplary chemotherapeutic agents are provided in Slapak and Kufe, Principles of Cancer Therapy, Chapter 86 in Harrison's Principles of Internal Medicine, 14th edition; Perry et ah, Chemotherapy, Ch. 17 in Abeloff, Clinical Oncology 2nd ed., 2000 Churchill Livingstone, Inc; Baltzer and Berkery. (eds): Oncology Pocket Guide to Chemotherapy, 2nd ed. St. Louis, Mosby-Year Book, 1995; Fischer Knobf, and Durivage (eds): The Cancer Chemotherapy Handbook, 4th ed. St. Louis, Mosby-Year Book, 1993).
[0098] Chimeric Antibody: An antibody having a variable region or part of variable region from a first species of a mammal and a constant region from a second species of a mammal.
[0099] Congenital Disorder: A condition or disease present at birth, which is inherited or brought about by environmental factors, such as the mother’s alcohol or drug consumption, nutritional intake and placental health. Examples of congenital disorders include, but are not limited to, congenital heart defect, cleft lip, sickle cell disease, alpha-thalassemia, beta- thalassemia, spinal muscular atrophy, spina bifida and Down syndrome.
[0100] Consumables: Laboratory equipment and reagents that must be replaced regularly as they wear out or are used. Consumable may include, but are not limited to, reagents, buffers,
disposable test tubes, beakers, pipettes, strips, gloves, facemasks, sample containers, syringes, centrifuge tubes, and swabs.
[0101] Contacting: Placement in direct physical association; includes both in solid and liquid form. Contacting can occur in vitro with isolated cells (for example in a tissue culture dish or other vessel) or in vivo by administering an active agent to a subject.
[0102] Control: A reference standard. In some examples, a control is a known value or range of values, such as one indicative of the presence or the absence of cystic fibrosis. In some examples, a control is a value or range of values, indicating a response in the absence of a therapeutic agent.
[0103] Cytokine: A substance released by one cell population that acts on another cell as intercellular mediator. Examples of cytokines include, but are not limited to, lymphokines, monokines; interleukins (ILs) such as IL-1, IL-la, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12, IL-15, including PROLEUKIN® rIL-2; a tumor necrosis factor such as TNF-a or TNF-b; and other polypeptide factors including LIF and kit ligand (KL).
[0104] Cytotoxic agent: A substance that inhibits or prevents the function of cells and/or causes destruction of cells.
[0105] Domain: A distinct functional and/or structural unit of a protein. A conserved domain refers to a domain that has been conserved during evolution. During evolution, changes at specific positions of an amino acid sequence in the protein have occurred in a way that preserve the physico-chemical properties of the original residues, and hence the structural and/or functional properties of that region of the protein.
[0106] Drug or Active Agent: A chemical substance or compound that induces a desired pharmacological or physiological effect, and includes therapeutically effective, prophylactically
effective, or systematically effective agents. The terms also encompass pharmaceutically acceptable, pharmacologically active derivatives and analogs of those active agents specifically mentioned herein, including, but not limited to, salts, esters, amides, pro-drugs, active metabolites, inclusion complexes, analogs, and the like. Suitable active agents that may be incorporated into the pharmaceutical compositions provided herein include, but are not limited to, adrenergic agents; adrenocortical steroids; adrenocortical suppressants; alcohol deterrents; aldosterone antagonists; amino acids; ammonia detoxicants; anabolic agents; analeptic agents; analgesic agents; androgenic agents; anesthetic agents; anorectic compounds; anorexic agents; antagonists; anterior pituitary activators and anterior pituitary suppressants; anti-acne agents; anti -adrenergic agents; anti allergic agents; anti-amebic agents; anti-androgen agents; anti-anemic agents; anti-anginal agents; anti-anxiety agents; anti-arthritic agents; anti-asthmatic agents and other respiratory drugs; anti- atherosclerotic agents; anti-bacterial agents; anti-cancer agents, including antineoplastic drugs, and anti-cancer supplementary potentiating agents; anticholinergics; anticholelithogenic agents; anti-coagulants; anti-coccidal agents; anti-convulsants; anti-depressants; anti-diabetic agents; anti- diarrheals; anti-diuretics; antidotes; anti-dyskinetics agents; anti-emetic agents; anti-epileptic agents; anti-estrogen agents; anti-fibrinolytic agents; anti-fungal agents; anti-glaucoma agents; antihelminthics; anti-hemophilic agents; anti -hemophilic Factor; anti -hemorrhagic agents; antihistamines; anti-hyperlipidemic agents; anti-hyperlipoproteinemic agents; antihypertensive agents; anti-hypotensives; anti-infective agents such as antibiotics and antiviral agents; anti inflammatory agents, both steroidal and non-steroidal; anti-keratinizing agents; anti-malarial agents; antimicrobial agents; anti-migraine agents; anti-mitotic agents; anti-mycotic agents; antinauseants; antineoplastic agents; anti-neutropenic agents; anti-obsessional agents; anti- parasitic agents; antiparkinsonism drugs; anti-pneumocystic agents; anti-proliferative agents; anti-
prostatic hypertrophy drugs; anti-protozoal agents; antipruritics; anti -psoriatic agents; antipsychotics; antipyretics; antispasmodics; anti-rheumatic agents; anti-schistosomal agents; anti- seborrheic agents; anti-spasmodic agents; anti-tartar and anti-calculus agents; anti -thrombotic agents; anti-tubercular agents; antitussive agents; anti -ulcerative agents; anti-urolithic agents; antiviral agents; GERD medications, anxiolytics; appetite suppressants; attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD) drugs; bacteriostatic and bactericidal agents; benign prostatic hyperplasia therapy agents; blood glucose regulators; bone resorption inhibitors; bronchodilators; carbonic anhydrase inhibitors; cardiovascular preparations including anti-anginal agents, anti-arrhythmic agents, beta-blockers, calcium channel blockers, cardiac depressants, cardiovascular agents, cardioprotectants, and cardiotonic agents; central nervous system (CNS) agents; central nervous system stimulants; choleretic agents; cholinergic agents; cholinergic agonists; cholinesterase deactivators; coccidiostat agents; cognition adjuvants and cognition enhancers; cough and cold preparations, including decongestants; depressants; diagnostic aids; diuretics; dopaminergic agents; ectoparasiticides; emetic agents; enzymes which inhibit the formation of plaque, calculus or dental caries; enzyme inhibitors; estrogens; fibrinolytic agents; fluoride anti cavity/anti decay agents; free oxygen radical scavengers; gastrointestinal motility agents; genetic materials; glucocorticoids; gonad-stimulating principles; hair growth stimulants; hemostatic agents; herbal remedies; histamine H2 receptor antagonists; hormones; hormonolytics; hypnotics; hypocholesterolemic agents; hypoglycemic agents; hypolipidemic agents; hypotensive agents; HMGCoA reductase inhibitors; immunizing agents; immunomodulators; immunoregulators; immunostimulants; immunosuppressants; impotence therapy adjuncts; inhibitors; keratolytic agents; leukotriene inhibitors; LHRH agonists; liver disorder treatments; luteolysin agents; memory adjuvants; mental performance enhancers; metal
chelators such as ethylenediaminetetraacetic acid, tetrasodium salt; mitotic inhibitors; mood regulators; mucolytics; mucosal protective agents; muscle relaxants; mydriatic agents; narcotic antagonists; nasal decongestants; neuroleptic agents; neuromuscular blocking agents; neuroprotective agents; nicotine; NMD A antagonists; non-hormonal sterol derivatives; nutritional agents, such as vitamins, essential amino acids and fatty acids; ophthalmic drugs such as antiglaucoma agents; oxytocic agents; pain relieving agents; parasympatholytics; peptide drugs; plasminogen activators; platelet activating factor antagonists; platelet aggregation inhibitors; post stroke and post-head trauma treatments; potentiators; progestins; prostaglandins; prostate growth inhibitors; proteolytic enzymes as wound cleansing agents; prothyrotropin agents; psychostimulants; psychotropic agents; radioactive agents; regulators; relaxants; repartitioning agents; scabicides; sclerosing agents; sedatives; sedative-hypnotic agents; selective adenosine A1 antagonists; serotonin antagonists; serotonin inhibitors; serotonin receptor antagonists; steroids, including progestogens, estrogens, corticosteroids, androgens and anabolic agents; smoking cessation agents; stimulants; suppressants; sympathomimetics; synergists; thyroid hormones; thyroid inhibitors; thyromimetic agents; tranquilizers; tooth desensitizing agents; tooth whitening agents such as peroxides, metal chlorites, perborates, percarbonates, peroxyacids, and combinations thereof; unstable angina agents; uricosuric agents; vasoconstrictors; vasodilators including general coronary, peripheral and cerebral; vulnerary agents; wound healing agents; xanthine oxidase inhibitors; and the like.
[0107] Effective amount: The amount of an active agent (alone or with one or more other active agents) sufficient to induce a desired response, such as to prevent, treat, reduce and/or ameliorate a progressive degenerative disorder. Effective amounts of an active agent, alone or with one or more other active agents, can be determined in many different ways, such as assaying
for a reduction in of one or more signs or symptoms associated with the condition, such as an uncontrolled inflammatory response condition, in the subject or measuring the level of one or more molecules associated with the condition to be treated.
[0108] Hydrogel: A water-swellable polymeric matrix that can absorb a substantial amount of water to form elastic gels. The matrix is a three-dimensional network of macromolecules held together by covalent or non-covalent crosslinks. Upon placement in an aqueous environment, dry hydrogels swell to the extent allowed by the degree of cross-linking.
[0109] Hydrophilic: A polymer, substance or compound that is capable of absorbing more than 10%/w of water at 100% relative humidity (rh).
[0110] Hydrophobic: A polymer, substance or compound that is capable of absorbing no more than 1%/w of water at 100% relative humidity (rh).
[0111] Hygroscopic: A polymer, substance or compound that is capable of absorbing more than 20 wt % of water at 100% relative humidity (rh).
[0112] Inhibiting a condition: Reducing, slowing, or even stopping the development of a condition, for example, in a subject who is at risk of developing or has a particular condition, such as a progressive genetic disease.
[0113] Interferon-type I: a large group of interferon proteins that bind to interferon receptors and regulate the activity of the immune system.
[0114] Lipophilic: A substance or compound that has an affinity for a non-polar environment compared to a polar or aqueous environment.
[0115] Localized application: The application of an active agent in a particular location in the body.
[0116] MicroRNAs (miRNAs): Short, highly conserved small noncoding RNAmolecules naturally occurring in the genomes of plants and animals. miRNAs are 17-27 nucleotides long and regulate posttranscriptional mRNA expression, typically by binding to the 3’ untranslated region (3’-UTR) of the complementary mRNA sequence, resulting in translational repression and gene silencing. miRNAs function in tumor suppression as oncogenes, and altered expression of particular miRNAs has been implicated in the onset and development of cancer.
[0117] Multiplex Analysis: Any analysis of two or more analytes in a sample, wherein each analyte is different from one another. The methods disclosed herein may include multiplex analysis of 2 or more, 5 or more, 10 or more, 50 or more, 100 or more, 500 or more or 1000 or more analytes in a sample.
[0118] Oil: Any fatty substance that is in liquid form at room temperature (25° C) and at atmospheric pressure (760 mmHg). An oily phase in a pharmaceutical composition may comprise at least one polar or apolar hydrocarbon-based oil.
[0119] Parenteral: a type of administration that includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. Compositions for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions prior to use.
[0120] Pathogen: An infectious agent capable of invading a host, which is transmitted through the air, sex, blood, and other bodily fluids, or through the fecal-oral route. Common pathogens include viruses, such as the human immunodeficiency virus (HIV) and hepatitis C; bacteria; fungi, such as yeast, mold, and mushrooms; and parasites, such as protozoa, helminths, and ectoparasites.
[0121] Permeation Enhancer: A natural or synthetic molecule that facilitates the transport of co-administered active agents across biological membranes.
[0122] pH Modifier: A molecule or buffer used to achieve desired pH control in a formulation. Exemplary pH modifiers include acids (e.g., acetic acid, adipic acid, carbonic acid, citric acid, fumaric acid, phosphoric acid, sorbic acid, succinic acid, tartaric acid, basic pH modifiers (e.g., magnesium oxide, tribasic potassium phosphate), and pharmaceutically acceptable salts thereof.
[0123] Pharmaceutically acceptable carriers: The pharmaceutically acceptable carriers useful in this disclosure are conventional. Remingtons’ Pharmaceutical Sciences , by E. W. Martin, Mack Publishing Co., Easton, PA, 19th Edition (1995), describes compositions and formulations suitable for pharmaceutical delivery of the compositions herein disclosed. The nature of the carrier can depend on the particular mode of administration being employed. For instance, parenteral applications usually include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle. In addition to biologically-neutral carriers, parenteral compositions may also contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like.
[0124] Proinflammatory cytokines: cytokines produced predominantly by activated macrophages and involved in the up-regulation of inflammatory reactions. Exemplary proinflammatory cytokines include, but are not limited to, IL-Ib, IL-6, and TNF-a. IL-Ib is released primarily by monocytes and macrophages during cell injury, infection, invasion, and inflammation.
[0125] Subject: A living multi-cellular vertebrate organism, a category that includes human and non-human mammals, as well as birds (such as chickens and turkeys), fish, and reptiles. Exemplary subjects include mammals, such as human and non-human primates, rats, mice, dogs, cats, rabbits, cows, pigs, goats, horses, and the like.
[0126] Surface or Body Surface: A surface located on the human body or within a body orifice. Thus, a "body surface" includes, by way of example, skin, teeth, skin or mucosal tissue, including the interior surface of body cavities that have a mucosal lining.
[0127] Topical administration: Delivery of an active agent to a body surface, such as, the skin or mucosa, as in, for example, topical drug administration in the prevention or treatment of various skin disorders.
[0128] Toxic agent: An agent or substance that can produce an adverse biological effect. Atoxic agent may be chemical, physical, or biological in nature. Toxic agents include, but are not limited to, inorganic substances such as lead, mercury, hydrofluoric acid, cyanide, and chlorine gas, organic compounds such as alcohol, radiations, coal dust, asbestos fibers, finely divided silicon dioxide, plant and pathogen toxins, snake venom, lithium and abused substances, such as marijuana and cocaine.
[0129] Transdermal: A route of administration by which active ingredients are delivered across the skin for systemic distribution. Examples include transdermal patches for drug delivery.
[0130] Under conditions sufficient to: A phrase that is used to describe any environment that permits the desired activity.
[0131] Water-Insoluble: A polymer, compound or composition with a solubility in water of less than 5%/w, less than 3%/w, or less than 1%/w, as measured in water at 20°C.
[0132] Water-Swellable: A polymer, substance or compound, that may absorb an amount of water greater than at least 25%/w of its own weight, or greater than at least 50%/w, upon immersion in an aqueous medium.
[0133] Referring now to FIGS. 1 A and IB, the figures show a diagram showing an example robot configuration (FIG. 1 A) and the assay sub-unit (FIG. IB) of an automated analyte detection and quantification system with direct sampling capabilities. The liquid handling robot may include a frame 8 for holding the robotic components. The robot may include a multichannel liquid handling pipette 1, a vacuum arm with removable pipette tips 2, integrated components 3 (e.g., power supply and vacuum pump), an open position for connector assembly 4, position for electrode assembly 5, an imaging unit 6 (which may be integrated with the robot, or and external imaging unit), and an associated computer 7.
[0134] With regard to FIG. IB, the sub-unit occupies one position within the “deck” of the robot layout, whereas reagents, pipette tips, or other consumables occupy other areas within the robot layout. The box and internal components are controlled via a computer and software. Communications may be in a wired or wireless format. The vacuum part 12 may designed to fit to a liquid handling control arm. The arm may move in 3 dimensions (e.g., in an x, y, z space) to remove liquid from wells. The vacuum part may have multiple tips, such as 8, 12, 16 or hundreds of tips.
[0135] The pipettor of the liquid handling robot travels back and forth between the sub unit and other locations on the robot deck and carries out pre-programmed assay functions. Liquids are delivered to the wells (or micro-wells) within the assay consumables, which are placed within the assay sub-unit. All assay functions are carried out via the laptop computer shown on the far left
in the robot layout. The sub-unit may include a connector assembly 9, electrode assembly 10 and a consumable chips & caddy 11.
[0136] Referring now to FIGS. 2A and 2B, the figures show delivery of consumables into sample wells of a chip caddy by individual pipette tips, which are guided and directed by the liquid handling robot. Electrode rails, which run diagonally in the image, do not interfere with the liquid delivery to the wells.
[0137] Referring now to FIGS. 3 A, 3B and 3C, the figures show four assay chips in a frame that can accommodate up to 128 samples at one time. The example chip caddy of FIG. 3 A may hold four assay chips. The chip caddy is compatible with most biological buffers and chemicals, so chips can be installed to the caddy and stored in wet conditions. Each well in the customized assay chip has a diameter of approximately 2mm and can hold about 2.5pl of volume. The assay chips are seated within the assay sub-unit. For example, in a 128 sample chip caddy, there would be a total of 256 wells. The 256 wells may be 2 mm sized. A corresponding number of electrodes would be used to apply voltage into the wells. In one example, considering the wells are 2 mm, electrodes may be in .5 mm and pipette tips are 07mm.
[0138] Referring now to FIGS. 4A and 4B, the figures provide a close-up view of the electrodes, which are a part of the electrode assembly and transmit electricity from the voltage power supply to the fluid-filled wells. The position of the electrodes in the system does not interfere with the liquid delivery from pipette tips.
[0139] Referring now to FIGS. 5A, 5B, 5C and 5D, the figures provide a view of the connector assembly (A), and electrode assembly (B, C) in their open positions. When these assemblies are closed, a hinged frame containing the electrodes makes contact with a hinged
electrical connector in the connector assembly, which applies voltage through a series of conductive pins. The consumable chip is housed at the bottom of the assembly (5D).
[0140] Referring now to FIGS. 6A and 6B, the figures show the conductive pins, which are integral components of the connector assembly. These pins direct voltage from the power supply cable onto the electrode rails.
[0141] Referring now to FIG. 7, the figure shows an example of a vacuum arm custom- designed to fit the liquid handling robot. A set of removable pipette tips can be attached to the bottom of the vacuum arm.
[0142] Referring now to FIGS. 8 A and 8B, the figures show the connector assembly in the open position.
[0143] Referring now to FIGS. 9A, 9B and 9C, the figures show the connector assembly (9 A), and the electrode assembly (9B) underneath the connector assembly, once the electrode assembly and connector assembly are closed and tightened (9C). The apparatus 900 may have a base 902 with a section or portion of the base 902 configured to receive or hold a chip caddy. The apparatus 900 may include a hingedly attached electrode assembly 904 attached to a portion of the apparatus 900. The apparatus may have a hingedly attached lid 906 that may be secured via a screw mechanism 908 with a post 910. The apparatus may have a raised bed 912 where the electrode assembly 904 may rest upon when in the open position.
[0144] Referring now to FIGS. 10A, 10B and IOC, the figures show the electrode assembly (A, B) in the open position, and the chip caddy (C), which is placed in the electrode assembly. Once the electrode assembly lid is closed, all electrodes are precisely positioned inside the corresponding wells of the assay chips and the electrical connectors are in contact with the electrode rails.
[0145] Referring now to FIGS. 11 A, 1 IB, 11C, and D the figures show the electrode frame 1100 and electrode rails 1102. The electrode rails have electrode tips 1104 spaced on the bottom portion of the electrode rail 1102. The electrode rail 1102 has end portions 1106 that clip the rail into position into frame 1100. FIG. 1 ID shows an example cross-sectional view of a portion of the electrode rail and an electrode tip.
[0146] Referring now to FIGS. 12A - 12C, the figures show the electrode frame 1100 and electrode rails 1102. In the example, the insulating electrode frame holds 16 electrode rails. Spring mechanism enables easy installation and removal of the electrode rails. FIG. 12C illustrates the electrode frame 1100 with a detailed cross-sectional view of the location on which the electrode rails 1100 are positioned, and the spring mechanism which pushes the electrode rail in the electrode frame.
[0147] Referring now to FIGS. 13A and 13B, the figures show an example of electrodes placed in the wells of an assay chip. One electrode of a first electrode rail is placed in the waste well on the left side of the diagram, and a second electrode of a second electrode rail is placed in the sample well on the left side of the diagram. One electrode of a third electrode rail is placed in the waste well on the right side of the diagram, and a fourth electrode of a fourth electrode rail is placed in the sample well on the right side of the diagram. As between the first and second electrode rails there is applied a voltage differential. As between the third and fourth electrode rails there is applied a voltage differential.
[0148] In the example, a first voltage is applied to the first electrode rail A of a predetermined value. A second voltage is applied to the second and third electrode rails B of a predetermined value. A conductive circuit connects the two middle (second and third) electrode
rails. A third voltage is applied to the fourth electrode rail C. FIG. 13B shows that there is a gap between electrode rails between the assay chips.
[0149] Referring now to FIG. 14, the figure provides a detailed view of the electrodes. The electrodes are angled at the top to prevent collisions with the pipette tips during movement.
[0150] Referring now to FIG. 15, the figure shows the standard curve for the human IL-1 Beta assay. Recombinant human IL1B was spiked into assay diluent at predetermined concentrations and the obtained calibrators were introduced into the disclosed system. 2.5pl of each calibrator was utilized within each sample well. The standard curve shows a broad dynamic range (5.5 log) with 1.9 pg/ml sensitivity.
[0151] Referring now to FIG. 16, the figure illustrates a method of an automated method for singleplex and multiplex detection and quantification of one or more analytes in a liquid sample. The method begins with separately introducing the liquid sample and one or more reagents into an automated analyte detection and quantification system with direct sampling capabilities (1610). The automated analyte detection and quantification system comprises a custom-designed automated liquid handling robot having microliter pipetting capabilities and programmed to deliver, add, aspirate or remove liquids to and from sample wells at defined time intervals or in predetermined conditions, and a system comprising a conductive connector assembly, an electrode assembly, a vacuum pump, a programmable, software-controlled voltage power supply and optionally an imaging system. The method continues with choosing an assay protocol from a list of pre-validated assay protocols to detect and quantify one or more target analytes (1620); closing the connector assembly and the electrode assembly within the connector assembly (1630); starting the automated system (1640); waiting 10 to 240 minutes to obtain data (1650); and calculating target analyte concentrations from the obtained data (1660).
[0152] Referring now to FIG. 17, the figure illustrates a method of processing a fluid having sample molecules. The method beings with providing a chip caddy including a frame with one or more assay chips, the assay chips each including one or more rows of a plurality of pairs of wells, wherein the pair of wells are interconnected via channels (1710). Electrodes may be placed into the wells of the chip assays (1720), or the wells may have electrodes disposed within the body chip assay. A fluid, including sample molecules, is placed into wells of the chip caddy such that the fluid contacts the electrodes (1730). For example, a fluid may be placed into wells of the assay chips using a robotic controlled pipettor, having multiple pipettor tips, such that the fluid contacts an electrode positioned within the well. A predetermined voltage via the electrodes is applied to cause the fluid to move from a well into the channel. (1740). The fluid is aspirated from the wells using a vacuum controlled aspirator to remove fluid from the wells of the chip caddy (1750).
Kit for Rapid and Highly Efficient Multiplex Analyte Detection and Quantification
[0153] Quick and accurate detection and quantification of target analytes and biomarkers in biological samples is essential for disease prevention strategies, diagnosis, and therapies. Most immunoassays are laborious and time-consuming, have multiple steps, and require hands-on user intervention.
[0154] Provided herein are kits for automated, pre-programmed, rapid and accurate singleplex or multiplex analyte detection and quantification in liquid samples.
[0155] The disclosed kits may include one or more of a chip caddy, consumable assay chips, a clamshell-style electrode assembly, an connector assembly, cables, a voltage power supply, a vacuum pump, a vacuum trap, and custom-designed fluid delivery and aspiration manifolds fitting different size liquid handling robot arms, and may further comprise one or more buffers, reagents and instructions for use.
[0156] These components are configured to fit different automated systems for singleplex or multiplex detection and quantification of macromolecules, and may be connected to different types of automated imagers. All components of the kit can be installed in only one direction and self-align: the assay consumables are placed into the electrode assembly, which fits under the connector assembly, which is then locked with fitting screws or a latch lock. Therefore, no training or expertise by the user is required.
[0157] Moreover, the disclosed components of the kits provided herein are configured to be used for a large number of tests, such as immunoassays, nucleic acid tests, clinical diagnostics, biomarker detection, and proteomic profiling, for the detection and quantification of proteins, peptides, antibodies, nucleic acids, biomarkers, hormones, metabolites, carbohydrates and lipids of interest, in liquid samples. Liquid samples may vary in volume from about 0.2pl to about IOOOmI.
[0158] The disclosed components of the kits provided herein are configured to connect to different types of automated imagers. Suitable automated imagers may comprise a LED or laser- induced fluorescence imaging reader equipped with features such as a fluorescence excitation source, optical filters, a photon measurement system, such as a camera or a photomultiplier tube system, objective lenses, systems for autofocus, auto-exposure, light intensity active monitoring and regulation, and automated image analysis and reporting systems.
[0159] The chip caddy contains the consumable assay chips. These assay consumables may be single use chips or reusable chips. The consumable chips are configured to contain wells designed to accept multiple samples and reagents for multiplex analyte detection and quantification.
[0160] The caddy is compatible with most biological buffers and chemicals, such that the assay chips can be installed to the caddy and stored in wet conditions. The chip caddy may contain 1 or more assay chips. Each assay chip may contain 2 sample wells, and each chip caddy may contain 16 sample wells, 64 sample wells, 256 sample wells, 640 sample wells, 1280 sample wells, 3200 sample wells, or 6400 sample wells. Each well has a diameter from about 1 mm to about 5 mm, or from about 1.5 mm to about 3 mm. Two or more wells may be connected via channels to allow for electric field-guided migration of reagents.
[0161] The electrode assembly houses a hinged precision electrode interface, which comprises multiple electrode rails. The electrode assembly comprises a bottom metal component housing a spring mechanism configured to align a chip caddy within the electrode assembly, and a top lid comprising an insulating electrode frame holding the electrode rails. The electrode rails are configured to be straight and aligned flat and parallel to the chip caddy, such that all electrodes are positioned properly at the edge of each well.
[0162] The electrode assembly is configured to be in either an open or closed position, and it has a specific configuration, such that it is configured to connect with the connector assembly. The electrode assembly can be washed, bleached, disinfected and reused as needed.
[0163] The conductive connector assembly comprises a lid and a printed circuit board (PCB) interface. The electrode connector assembly is configured to interface with the electrode assembly and transmit electricity to the electrode rails within the electrode assembly, while providing space for liquid handling access to the assay chips. Once the connector assembly and the electrode assembly are closed into the appropriate position, each electrode in the electrode rails is configured to sit on the edge of each well and to receive electricity through the connector assembly. Each electrode may have a thickness between 0.1 mm and 1 mm, or between 0.3 mm
and 0.7 mm. In addition, each electrode is a laser-welded platinum electrode comprising an angled top to allow contact with the liquid in the wells and prevent collusion with automated microtips delivering or aspirating liquids to or from the wells. The connector assembly and electrode assembly are configured to hold the consumable chips in place and deliver and maintain electrical conductivity within all wells simultaneously with millimeter or sub-millimeter spatial accuracy.
[0164] The voltage power supply may comprise from one to ten independent outputs for single or multiple connections and deliver a voltage from 0 to 5,000 volts.
[0165] The components of the disclosed kits, including the vacuum system and the voltage power supply, are configured to be integrated and connected to any software and imaging system linked to any automated system for singleplex or multiplex detection and quantification of macromolecules, to enable image analysis and advanced data analysis.
[0166] The disclosed kits are configured to enable detection and quantification of one or more analytes in liquid samples using any automated analysis system. Liquid samples may include, but are not limited to, biological samples, such as blood, serum, and urine, cell suspensions, cell supernatants and lysates, plant extracts, sea water, microfilm fluids, running water, and beverages. Liquid samples may be in a volume amount from about 0.2pl to about IOOOmI. Analytes may include, but are not limited to, proteins, peptides, antibodies nucleic acids, biomarkers, hormones, metabolites, carbohydrates and lipids, or other macromolecules of interest. Suitable detection methods include, but are not limited to, immunoassays, nucleic acid tests, clinical diagnostics, biomarker detection, and proteomic profiling.
[0167] The components of the disclosed kits may be used with any automated liquid handling system to enable application of directional electric fields to electrokinetically and sequentially transport samples and/or reagents through the system. Additionally, the components
of the disclosed kits are configured to allow any liquid handling robot to precisely transfer, dispense, deliver or aspirate liquids to and from sample wells at different times or in different cycles, in order to capture and bind target analytes. Capturing and binding target analytes may include, without limitations, sandwich antibody detection, enzyme-labeled antigen reaction, fluorometric detection, in situ hybridization, microarray technology, affinity binding, radioactive and colorimetric binding.
[0168] In some embodiments, the components of the disclosed kits may fit into an automated analyte detection and quantification system with direct sampling capabilities. This system automates detection and quantification workflows of macromolecules, such as proteins, peptides, antibodies, nucleic acid markers, hormones, metabolites, carbohydrates, lipids and other analytes of interest, including sample dilution, and provides complex sigmoidal plotting and curve fitting data from which the user can calculate target analyte concentrations, within 10 minutes to 4 hours time.
[0169] In some embodiments, the automated analyte detection and quantification system with direct sampling capabilities is a system in which all steps are automated and pre-programmed, such that little to no manual intervention is required. In some embodiments, the automated analyte detection and quantification system with direct sampling capabilities is a system in which not all steps are automated and pre-programmed, such that some manual intervention may be required, for example, to move the chip caddy from a first location to a second location. The automated analyte detection and quantification system integrates microscale liquid handling, biomolecular measurement assay and data readout, such that the user only controls the system via external computer or integrated touch screen. Accordingly, the disclosed system may be operated by a person with minimal lab training in an automated fashion. Moreover, the disclosed automated
analyte detection and quantification system performs multiplex analysis with high efficiency and with sub-pg/ml sensitivity, thus providing a solution to the aforementioned challenges.
[0170] The disclosed system comprises an automated liquid handling robot and an assay subunit. The automated liquid handling robot is a custom-designed robot having microliter pipetting capabilities, and programmed to deliver, add, aspirate or remove liquids from sample wells at defined time intervals or in pre-determined conditions. The liquid handling robot is capable of automatically carrying out all necessary sample preparation steps before an assay, such as reagent mixing and sample dilution.
[0171] The automated liquid handling robot comprises a custom-designed arm comprising an aspiration manifold configured to be connected to a vacuum line. The size of the manifold may be varied to adjust for attachment of macrotips or microtips, such that the robot delivers or aspirates reagents, buffers, or the like into sample wells as needed, with millimeter or sub-millimeter accuracy.
[0172] The assay subunit comprises the conductive electrode connector assembly comprising a lid and a printed circuit board (PCB) interface, a clamshell-style electrode assembly configured to fit underneath and connect to the electrode connector assembly and to hold consumable assay chips, a vacuum pump, and a programmable voltage power supply connected to the connector interface. The electrode assembly houses a hinged precision electrode interface, which comprises multiple electrode rails. All components of the disclosed kits can be installed in only one direction and self-align: the assay chips are placed into the electrode assembly, which fits in place against the connector assembly, which is then locked with fitting screws or a latch lock. Therefore, no training or expertise by the user is required.
[0173] The system may further comprise an automated imager. The automated imager may be placed directly underneath the assay subunit or it may be a separate unit. The automatic imager may comprise a fluorescence imaging reader equipped with features such as a fluorescence excitation channels, optical filters, a photon measurement system such as a camera or photomultiplier tube system), objective lenses, an autofocus system, auto exposure, light intensity monitoring/regulation systems, and automated image analysis and reporting systems.
[0174] The voltage power supply may comprise one to ten independent outputs for single or multiple connections and deliver a voltage from 0 to 5,000 volts. The software is configured to integrate and connect the liquid handling robot, the vacuum system, and the voltage power supply, to fully automate the assay running steps and to enable image analysis and advanced data analysis. The power supply for example, may have 8 independent channels all of which can be operated independently. The channels can be used to apply voltage to the respective electrode assemblies. In one embodiment, the voltage power supply may have a voltage in the 0-1500V range with a resolution of +/- 50mv; current of a 12mA total, 10mA max per channel with a 500nA resolution.
[0175] When an imaging system is integrated with the body of the robot, the software is configured to connect the liquid handling robot, the vacuum system, the voltage power supply and the imaging system, to fully automate the assay running and imaging steps, and enable image analysis and advanced data analysis.
[0176] The disclosed automated system is configured to detect the presence of one or more analytes of interest in a liquid sample and quantify detected amounts of one or more analytes within a period of time from about 10 minutes to about 4 hours. Liquid samples may include, but are not limited to, biological samples, such as blood, serum, and urine, cell suspensions, cell supernatants and lysates, plant extracts, sea water, microfilm fluids, running water, and beverages. Analytes
may include, but are not limited to, proteins, peptides, antibodies, nucleic acids, biomarkers, hormones, metabolites, carbohydrates and lipids, or other macromolecules of interest. Suitable detection methods include, but are not limited to, immunoassays, nucleic acid tests, clinical diagnostics, biomarker detection, and proteomic profiling.
[0177] The disclosed automated system is configured to allow one or more liquid samples and one or more reagents to be introduced separately and at different times into the system. Liquid samples may be in a volume amount from about 0.2 pi to about IOOOmI.
[0178] The disclosed automated system is configured to apply directional electric field to the electrode assembly, such that one or more reagents are electrokinetically and sequentially transported through the system to the one or more samples. The disclosed automated system is also configured to allow the liquid handling robot to precisely transfer, dispense into, deliver to or aspirate from different samples one or more reagents at different times or in different cycles, in order to capture and bind target analytes. Capturing and binding target analytes may include, without limitations, sandwich antibody detection, enzyme-labeled antigen reaction, fluorometric detection, in situ hybridization, microarray technology, affinity binding, radioactive and colorimetric binding.
[0179] Thus, the kits disclosed herein provide accurate, rapid and effective detection and quantification of analytes in liquid samples.
EXAMPLE
Highly Efficient IL-1 Beta Measurements from Volume-Limited Renal Carcinoma Cells Treated with Different Drug Combinations
[0180] The goal of the study was to assess the variation of ILl Beta concentrations in immune response to various drug/treatment combinations applied to renal carcinoma cell cultures obtained from subjects in clinical trial.
[0181] ILl Beta (ILIB) is an Interleukin 1 family cytokine that plays an important role in inflammatory response. It is involved in cell proliferation, differentiation and apoptosis and, because of its potential to modulate acute inflammation, ILIB is a biomarker of interest for therapeutic applications and drug development safety assessments. In renal cell carcinoma, ILIB is one of the major mediators of local and systemic inflammation.
[0182] In this study, ILIB was measured for biomarker-assisted therapy. Primary tumor cells were removed via micro-biopsy from clinical trial patients undergoing treatment for renal cell carcinoma. The tumor cells were then incubated in vitro with combinations of therapeutics to determine response and impact on secreted protein biomarkers. The goal of this study was to preserve precious samples from the tumor cells and compare the efficacy of microvolume immunoassays to conventional technology.
[0183] To generate a calibration curve, recombinant human ILIB was spiked into an assay diluent at predetermined concentrations and the calibrators thus obtained were introduced into an automated analyte detection and quantification system with direct sampling capabilities as provided herein. 2.5pl of each calibrator was utilized within each sample well. As shown in Figure 15, results demonstrated a broad dynamic range (5.5 log) with 1.9pg/ml sensitivity. The R2 of the 5-parameter sigmoid fit was 0.9994. The disclosed system did not exhibit any hook effect artifacts at high target concentrations (data not shown). The lack of artifacts and the broad dynamic range make the automated analyte detection and quantification system with direct sampling capabilities as provided herein suitable for quick, highly efficient detection and
quantification of analytes, as it offers a simple one-step assay, with minimal or no involvement of the user and with no need to repeat the analysis multiple times.
[0184] The available sample volume that was tested for each condition was IOmI. Of the IOmI sample, a 2.5 pi aliquot was diluted 4 times into the assay diluent. From the resulting IOmI of total diluted sample, 2.5 pi were loaded into the sample wells. The remaining 7.5m1 of the original sample were preserved for future assays. The assay was completed in less than an hour from start to finish in a hands-free, fully automated manner. The data presented here were automatically calculated using analysis software.
FURTHER KIT EXAMPLES
[0185] Example 1A. A kit for automated and pre-programmed singleplexed and multiplexed detection and quantification of one or more analytes in a liquid sample, wherein the kit comprises one or more components, and wherein the one or more components comprise a chip caddy, consumable assay chips, an electrode assembly, an electrical connector assembly, one or more cables, a voltage supply, a vacuum pump, a vacuum trap, custom-designed manifolds, one or more buffers, reagents and instructions for use.
[0186] Example 2A. The kit of example 1A, wherein the components of the kit are configured to fit different automated systems and to allow for singleplex or multiplex detection and quantification of macromolecules, and to be connected to different automated imagers.
[0187] Example 3A. The kit of example 2A, wherein the components of the kit are configured to subject a liquid sample to an immunoassay, nucleic acid test, clinical diagnostic tests, biomarker detection, and/or multiplexed proteomic profiling.
[0188] Example 4A. The kit of example 3A, wherein the components of the kit are configured to subject a liquid sample to target analyte detection and quantification.
[0189] Example 5A. The kit of example 4A, wherein the target analyte is one or more of a protein, peptide, antibody, nucleic acid, biomarker, hormone, metabolite, carbohydrate or lipid.
[0190] Example 6A. The kit of example 5A, wherein the liquid sample is in a volume amount from about 0.2pl to about IOOOmI.
[0191] Example 7A. The kit of example 6A, wherein the automated imagers comprise one or more of a fluorescence excitation source, an optical filter, a photon measurement system, an objective lens, a system for autofocus, auto exposure, or light intensity monitoring and regulation, and an automated image analysis and reporting system.
[0192] Example 8A. The kit of example 7A, wherein the chip caddy contains 1 or more consumable assay chips.
[0193] Example 9A. The kit of example 8A, wherein the consumable chips are single use chips.
[0194] Example 10A. The kit of example 9A, wherein the consumable chips are reusable chips.
[0195] Example 11 A. The kit of example 8A, wherein the consumable chips comprise 2 sample wells, 16 sample wells, 64 sample wells, 256 sample wells, 640 sample wells, 1280 sample wells, 3200 sample wells, or 6400 sample wells.
[0196] Example 12A. The kit of example 11 A, wherein each well has a diameter from about 1 mm to about 5 mm, or from about 1.5 mm to about 3 mm, and wherein two or more wells are interconnected via channels.
[0197] Example 13A. The kit of example 1 A, wherein the electrode assembly is configured to fit in place under the connector assembly lid and to hold consumable assay chips.
[0198] Example 14A. The kit of example 13A, wherein the electrode assembly comprises a hinged precision electrode interface connectable to the programmable voltage power supply.
[0199] Example 15 A. The kit of example 14A, wherein the voltage power supply comprises from one to ten independent outputs.
[0200] Example 16A. The kit of example 15 A, wherein the electrode assembly comprises a bottom component housing a spring mechanism configured to align a chip caddy within the electrode assembly, and a top lid comprising an insulating electrode frame holding electrode rails.
[0201] Example 17A. The kit of example 16A, wherein the electrode rails are configured to be straight and aligned flat and parallel to the chip caddy.
[0202] Example 18 A. The kit of example 17A, wherein the electrode assembly is removable from the connector assembly.
[0203] Example 19A. The kit of example 18 A, wherein the electrode assembly is washable, bleachable, disinfectable and reusable.
[0204] Example 20A. The kit of example 19A, wherein the connector assembly comprises a lid and a printed circuit board (PCB) interface.
[0205] Example 21A. The kit of example 20A, wherein the connector assembly is attachable to an automated liquid handling robot’s base and it is configured to transmit electricity to the electrode rails within the electrode assembly.
[0206] Example 22 A. The kit of example 21 A, wherein each electrode has a thickness between 0.1 mm and 1 mm, or between 0.3 mm and 0.7 mm.
[0207] Example 23A. The kit of example 22A, wherein each electrode is a laser-welded platinum electrode comprising an angled top.
[0208] Example 24A. The kit of example 23A, wherein the liquid handling robot, the vacuum system, the voltage power supply and the imaging system are configured to be integrated and connected by a custom software.
[0209] Example 25 A. The kit of example 1 A, wherein the custom-designed manifolds are configured to be connectable to a vacuum line and for macro tip or micro tip attachment.
[0210] Example 26A. The kit of example 25A, wherein the custom-designed manifolds are configured to be attached to an automated liquid handling robot to deliver or aspirate one or more assay reagents to one or more wells in the consumable chips.
[0211] Example 27A. The kit of example 1A, wherein the components of the kit are configured to fit into an automated analyte detection and quantification system with direct liquid sampling and sample dilution capabilities, and wherein the automated analyte detection and quantification system with direct liquid sampling and sample dilution capabilities comprises an automated liquid handling robot having microliter pipetting capabilities, programmed to deliver, add, aspirate or remove liquids to and from sample wells and assay chip wells at defined time intervals or in pre-determined conditions, and capable of automatically carrying out all sample preparation steps.
[0212] Example 28A. The kit of example 27 A, wherein the automated liquid handling robot comprises a custom-designed arm comprising an aspiration manifold connected to a vacuum line and configured for micro tip attachment.
[0213] Example 29A. The kit of example 28A, wherein the automated analyte detection and quantification system further comprises an automated imager.
[0214] Example 30A. The kit of example 29A, wherein the automated imager is integrated into the automated analyte detection and quantification system with direct liquid sampling and sample dilution capabilities.
[0215] Example 31 A. The kit of example 30A, wherein the automated imager is separate from the automated analyte detection and quantification system with direct liquid sampling and sample dilution capabilities.
[0216] Example 32A. The kit of example 30A, wherein the automatic imager comprises a fluorescence reader.
[0217] Example 33A. The kit of example 32A, wherein the custom software integrates and connects the liquid handling robot, the vacuum system, the voltage power supply and the automatic imager, are configured to be integrated and connected by a custom software.
[0218] Example 34A. The kit of example 33A, wherein the automated liquid handling robot is configured to deliver or aspirate one or more assay reagents to one or more wells in the consumable assay chips at different times or in different sequences.
[0219] Example 35 A. The kit of example 34A, wherein the automated system is configured to detect the presence of one or more analytes in a liquid sample and quantify detected amounts of one or more analytes within a period of time from about 10 minutes to about 4 hours.
[0220] Example 36A. The kit of example 35A, wherein the liquid sample is one or more of a biological sample, a cell suspension, supernatant or lysate, plant extracts, seawater, a microfilm fluid, water samples, or a beverage.
[0221] Example 37A. The kit of example 36A, wherein the biological sample is blood, serum, urine, or a body fluid from a human or animal.
[0222] Example 38 A. The kit of example 37 A, wherein the automated analyte detection and quantification system is configured to detect and quantify one or more of a protein, peptide, antibody, nucleic acid, biomarker, hormone, metabolite, carbohydrate and lipid.
[0223] Example 39A. The kit of example 38A, wherein detection comprises one or more of an immunoassay, nucleic acid test, multiplex diagnostic test, biomarker measurement or detection, and/or proteomic profiling.
[0224] Example 40 A. The kit of example 39A, wherein the automated system is configured to allow one or more liquid samples and one or more reagents to be separately and at different times introduced into the system.
[0225] Example 41 A. The kit of example 40A wherein the liquid sample volume is from about 0.2pL to about lOOOpL.
[0226] Example 42 A. The kit of example 41 A, wherein the automated analyte detection and quantification system is configured to apply directional electric field, such that one or more reagents are electrokinetically and sequentially transported from one well to another on the assay chips.
[0227] Example 43 A. The kit of example 42A, wherein the automated analyte detection and quantification system is configured to allow a liquid handling robot to precisely transfer, dispense into, deliver to or aspirate from different samples or one or more reagents at different times or in different cycles, in order to perform assays on target analytes.
[0228] Example 44A. The kit of example 43 A, wherein the assays comprise one or more of sandwich antibody detection, enzyme-labeled antigen reaction, fluorometric detection, in situ hybridization, microarray technology, affinity binding, radioactive and colorimetric binding.
[0229] It should be recognized that illustrated embodiments are only examples of the disclosed product and methods and should not be considered a limitation on the scope of the invention. Rather, the scope of the invention is defined by the following claims. We therefore claim as our invention all that comes within the scope and spirit of these claims.
Automated System for Rapid and Highly Efficient Multiplex Analyte Detection and Quantification
[0230] Quick and accurate detection and quantification of target analytes and biomarkers in biological samples is essential for disease prevention strategies, diagnosis, and therapies. Most immunoassays are laborious and time-consuming, have multiple steps, and require hands-on user intervention.
[0231] Provided herein is an automated analyte detection and quantification system with direct sampling capabilities, which automates detection and quantification workflows of macromolecules, such as proteins, peptides, antibodies, nucleic acid markers, hormones, metabolites, carbohydrates, lipids and other analytes of interest, including sample dilution, and provides complex sigmoidal plotting and curve fitting data from which the user can calculate target analyte concentrations, within 10 minutes to 4 hours time.
[0232] In some embodiments, the automated analyte detection and quantification system with direct sampling capabilities is a system in which all steps are automated and pre-programmed, such that little to no manual intervention is required. In some embodiments, the automated analyte detection and quantification system with direct sampling capabilities is a system in which not all steps are automated and pre-programmed, such that some manual intervention may be required, such as, for example, to move the chip caddy from a first location to a second location.
[0233] The automated analyte detection and quantification system is configured to integrate microscale liquid handling, biomolecular measurement assay and data readout, such that the user only controls the system via external computer or integrated touch screen. Accordingly, the disclosed system may be operated by a person with minimal lab training in an automated fashion. Moreover, the disclosed automated analyte detection and quantification system performs multiplex analysis with high efficiency and with sub-pg/ml sensitivity, thus providing a solution to the aforementioned challenges.
[0234] The disclosed system comprises an automated liquid handling robot and an assay subunit. The automated liquid handling robot is a custom-designed robot having microliter pipetting capabilities, and programmed to deliver, add, aspirate or remove liquids from sample wells at defined time intervals or in pre-determined conditions. The liquid handling robot is additionally configured to automatically carry out all necessary sample preparation steps before an assay, such as reagent mixing and sample dilution.
[0235] The automated liquid handling robot comprises a custom-designed and manufactured arm comprising an aspiration manifold configured to be connected to a vacuum line. The size of the manifold may be varied to adjust for attachment of macrotips or microtips, such that the robot may deliver or aspirate reagents, buffers, or the like into sample wells as needed, with millimeter or sub-millimeter accuracy.
[0236] The assay subunit is a system that comprises a conductive connector assembly comprising a lid and a printed circuit board (PCB) interface, an electrode assembly configured to fit into the connector assembly and to hold consumable assay chips, a vacuum pump, and a programmable voltage power supply connected to the connector interface.
[0237] The electrode assembly houses a hinged precision electrode interface, which comprises multiple electrode rails. All components of the assay subunit can be installed in only one direction and self-align: the assay chips are placed into the electrode assembly, which fits under the connector assembly, which is then locked with fitting screws or a latch lock. Therefore, no training or expertise by the user is required.
[0238] The system may further comprise an automated imager. The automated imager may be integrated into the system, or it may be a separate unit from the system. The automatic imager may comprise a fluorescence imaging reader equipped with features, such as a microscope, excitation channels, optical filters, a photon measurement system such as a camera or photomultiplier tube system, objective lenses, an autofocus system, auto exposure, light intensity active monitoring and regulation systems, and/or an automated image analysis and reporting system.
[0239] The voltage power supply may comprise from one to ten independent outputs for single or multiple connections and it is configured to deliver a voltage from 0 to 5,000 volts. The software is configured to integrate and connect the liquid handling robot, the vacuum system, the voltage power supply and the imaging system, to enable image analysis and advanced data analysis.
[0240] The connector assembly may be fixed to a plate at the automated liquid handling robot’s base, and it is configured to hold the electrode assembly and transmit electricity to the electrode rails within the electrode assembly, while providing space for liquid handling access to the assay chips.
[0241] The electrode assembly comprises a bottom metal component housing a spring mechanism configured to align a chip caddy within the electrode assembly, and a top lid
comprising an insulating electrode frame holding the electrode rails. The electrode rails are configured to be straight and aligned flat and parallel to the chip caddy, such that all electrodes are positioned properly at the edge of each well.
[0242] The electrode assembly is configured to be in either an open or closed position, and it is configured to connect with the connector assembly. The electrode assembly can be washed, bleached, disinfected and reused as needed.
[0243] The chip caddy contains the consumable assay chips. These consumable assay chips may be single use chips or reusable chips. The consumable assay chips are configured to contain wells designed to accept multiple samples and reagents for multiplex analyte detection and quantification.
[0244] The caddy is compatible with most biological buffers and chemicals, such that the assay chips can be installed to the caddy and stored in wet conditions. The chip caddy may contain f or more assay chips. Each assay chip may contain 2 sample wells, and each chip caddy may contain f6 sample wells, 64 sample wells, 256 sample wells, 640 sample wells, f280 sample wells, 3200 sample wells, or 6400 sample wells. Each well has a diameter from about f mm to about 5 mm, or from about f .5 mm to about 3 mm. Two or more wells may be connected via channels to allow for electric field-guided migration of reagents. In one example, the channels may be cylindrical in shape, or other suitable shapes, such as D-shaped, square, oval, etc. The dimension of the channel may be for .5 micrometers to 1000 micrometers in width and/or depth. The length of the channels can be of any suitable lengths, for example from a few millimeters to a few centimeters. The automated liquid handling robot is configured to deliver or aspirate one or more assay reagents in appropriate sequence to one or more wells within the consumable chips.
[0245] Once the connector assembly and the electrode assembly within the connector assembly are closed into the appropriate position, each electrode in the electrode rails is configured to sit on the edge of each well and to receive electricity through the connector assembly. Each electrode may have a thickness between 0.1 mm and 1 mm, or between 0.3 mm and 0.7 mm. In addition, each electrode is a laser-welded platinum electrode comprising an angled top to allow contact with the liquid in the wells and prevent collisions with the microtips delivering or aspirating liquids to or from the wells.
[0246] The assay subunit is configured to hold the consumable chips in place and deliver and maintain electrical conductivity within all wells simultaneously with millimeter or sub millimeter spatial accuracy.
[0247] The disclosed automated system is configured to detect the presence of one or more analytes of interest in a liquid sample and quantify detected amounts of one or more analytes within a period of time from about 10 minutes to about 4 hours. Liquid samples may include, but are not limited to, biological samples, such as blood, serum, and urine, cell suspensions, cell supernatants and lysates, plant extracts, sea water, microfilm fluids, running water, and beverages. Analytes may include, but are not limited to, proteins, peptides, antibodies, nucleic acids, biomarkers, hormones, metabolites, carbohydrates and lipids, or other macromolecules of interest. Suitable detection methods include, but are not limited to, immunoassays, nucleic acid tests, clinical diagnostics, biomarker detection, and proteomic profiling.
[0248] The disclosed automated system is configured to allow one or more liquid samples and one or more reagents to be introduced separately and at different times into the system. Liquid samples may be in a volume amount from about 0.2pl to about IOOOmI.
[0249] The disclosed automated system is configured to apply directional electric field to the assay chips, such that one or more reagents are electrokinetically and sequentially transported from one well to the other. The disclosed automated system is also configured to allow the liquid handling robot to precisely transfer, dispense into, deliver to or aspirate from different samples one or more reagents at different times or in different cycles, in order to carry out sample preparation steps, or capture and bind target analytes. Capturing and binding target analytes may include, without limitations, sandwich antibody detection, enzyme-labeled antigen reaction, fluorometric detection, in situ hybridization, microarray technology, affinity binding, radioactive and colorimetric binding.
Rapid and Highly Efficient Multiplex Analyte Detection and Quantification Protocol with the Disclosed Automated System
[0250] Also provided herein are automated methods for singleplex and multiplex detection and quantification of one or more analytes in a liquid sample, which require minimal or no manual interventions. The disclosed automated methods comprise (a) separately introducing the liquid sample and one or more reagents into the disclosed automated analyte detection and quantification system with direct sampling capabilities; (b) choosing an assay protocol from a list of pre validated assay protocols to detect and quantify one or more target analytes; (c) closing the connector assembly and the electrode assembly within the connector assembly; (d) starting the automated system; (e) waiting 10 to 240 minutes; and (f) calculating target analyte concentrations from detection and quantification data presented by the automated system.
[0251] The step of separately introducing the liquid samples and reagents into the automated analyte detection and quantification system may comprise automated dilution of the fluid samples and/or the reagents with a loading medium prior to delivery of each liquid sample
and delivering each reagent into separate, inter-connected wells of the consumable assay chips by the automated liquid handling robot, and placing a chip caddy containing one or more consumable assay chips into the electrode assembly located below the connector assembly. Assay chip placement and electrode assembly may be automated and pre-programmed or performed manually.
[0252] Once the system is started, it applies a voltage difference through the conductive pins in the connector assembly to the electrode rails within the electrode assembly to generate a directional electric field between the wells and transport reagent or analyte molecules from well- to-well. The disclosed automated methods may comprise several cycles of automated fluid delivery and/or aspiration by the liquid handling robot, followed by automated electric field application to move one or more reagent or analyte molecules from well-to-well.
[0253] The chip caddy is then transported manually or in automated fashion to a reader for detection and quantification of immobilized analytes. Analyte detection may include labeling the analyte of interest with a detectable label and detecting the signal emitted by the detectable label. Detectable labels include, but are not limited to, a fluorescent label, a colorimetric label, a chemo luminescent label, a color reagent, an enzyme-linked reagent, an antibody-linked reagent, a radiolabel or a magnetic label. Analyte quantification may include any quantitative analysis, such as advanced data analysis, display of results, composing reporting structures, validation of image- derived metrics with anatomic and physiological parameters, and the use of metrics in research, prevention, diagnosis, prognosis, and medical treatment.
[0254] Thus, the system and methods disclosed herein provide accurate, rapid and effective detection and quantification of analytes in liquid samples.
EXAMPLE
Highly Efficient IL1 Beta Measurements from Volume-Limited Renal Carcinoma Cells
Treated with Different Drug Combinations
[0255] The goal of the study was to assess the variation of ILl Beta concentrations in immune response to various drug/treatment combinations applied to renal carcinoma cell cultures obtained from subjects in clinical trial.
[0256] ILl Beta (ILIB) is an Interleukin 1 family cytokine that plays an important role in inflammatory response. It is involved in cell proliferation, differentiation and apoptosis and, because of its potential to modulate acute inflammation, ILIB is a biomarker of interest for therapeutic applications and drug development safety assessments. In renal cell carcinoma, ILIB is one of the major mediators of local and systemic inflammation.
[0257] In this study, ILIB was measured for biomarker-assisted therapy. Primary tumor cells were removed via micro-biopsy from clinical trial patients undergoing treatment for renal cell carcinoma. The tumor cells were then incubated in vitro with combinations of therapeutics to determine response and impact on secreted protein biomarkers. The goal of this study was to preserve precious samples from the tumor cells and compare the efficacy of microvolume immunoassays to conventional technology.
[0258] To generate a calibration curve, recombinant human ILIB was spiked into an assay diluent at predetermined concentrations and the calibrators thus obtained were introduced into an automated analyte detection and quantification system with direct sampling capabilities as provided herein. 2.5 pi of each calibrator was utilized within each sample well. As shown in Figure 15, results demonstrated a broad dynamic range (5.5 log) with 1.9 pg/ml sensitivity. The R2 of the 5-parameter sigmoid fit was 0.9994. The disclosed system did not exhibit any hook effect artifacts at high target concentrations (data not shown). The lack of artifacts and
the broad dynamic range make the automated analyte detection and quantification system with direct sampling capabilities as provided herein suitable for quick, highly efficient detection and quantification of analytes, as it offers a simple one-step assay, with minimal or no involvement of the user and with no need to repeat the analysis multiple times.
[0259] The available sample volume that was tested for each condition was 10 pi. Of the 10 mΐ sample, a 2.5 mΐ aliquot was diluted 4 times into the assay diluent. From the resulting 10 mΐ of total diluted sample, 2.5 mΐ were loaded into the sample wells. The remaining 7.5 mΐ of the original sample were preserved for future assays. The assay was completed in less than an hour from start to finish in a hands-free, fully automated manner. The data presented here were automatically calculated using analysis software.
[0260] Example Robotic Operation for an Assay
[0261] Step 1. The robot pipettor first picks up pipettes.
[0262] Step 2. The robot pipettor performs sample dilutions (e.g., places about a 9 mΐ and places into tubes). Then the robot takes 1 mΐ from raw samples and mixes the raw samples with the 9 mΐ of the diluent. The robot pipettor would repeat this process for multiple samples.
[0263] Step 3. The robot pipettor then pick up 2 mΐ of buffer and move to the assay chip location. Before dispensing the buffer, the robot aspirator clears up liquid from the waste wells of the chip assays. The robot pipettor then dispenses the buffer to one of the wells of the pair of wells.
[0264] Step 4. The robot pipettor repeats the steps 1-3 but for sample fluids. The robot pipettor picks up and dispenses sample into samples into the samples wells. Before dispensing the sample into the sample wells, the robot aspirator clears up liquid from the sample wells of the chip assays of the chip caddy.
[0265] Step 5. The robot pipettor then dispenses pipettor tips and parks into position. At this point, the samples and the buffer have been filled into the respect wells.
[0266] Step 6. The electrode assembly is positioned into place causing the electrodes tips to be submerged into the respective pairs of waste and sample wells. A voltage is then applied for a set period of time thereby causing a current between the fluid in the pair of wells.
[0267] Step 7. When the duration of applied voltage is completed, the robot pipettor repeat step 3. This may be done for example, three times to wash wells of the chip caddy.
[0268] Step 8. Steps 4 through 5 may be repeated to add new samples to the washed wells, and then the voltage in step 6.
[0269] Step 9. After the samples processing is done, an imager obtains images of all of the location of the pairs of wells of the chip caddy (for example, 96 locations). The digital imagery may be in two spectrums. One primary image (to show exposure), and a second image to show three to nine different time exposures (e.g, 20ms, 400ms, 800ms, 1600ms, 3200ms.)
[0270] Step 10. The images are then transferred to a computer where software performs an analysis and generates data pertaining to the processed samples.
[0271] For each of the transfer or washing steps described above, the robotic system may perform the steps of: Step 1. The robotic pipettor picks up pipette tips. Step 2. The robotic pipettor picks up liquid. Step 3. A vacuum manifold is used to extract fluid and clean the wells. Step 4. The robotic pipettor dispenses to the cleaned wells. Step 5. The robotic pipettor discards the pipettes.
[0272] Example Robotic Operation for an Assay
[0273] In another example, the robotic system performs multiple steps.
[0274] Step 1. The robotic system performs an operation to dilute samples.
[0275] Step 2. The robotic system provides a buffer refresh to all wells of an assay chip.
[0276] Step 3. The robotic system then transfers samples to wells of the assay chip.
[0277] Step 4. The robotic system then applies a predetermined voltage the electrode rails of the assembly to transport sample into the channel interconnecting the pairs of wells.
[0278] Step 5. The robotic system washes the wells multiple times.
[0279] Step 6. The robotic system then applies a predetermined voltage to electrode rails of the electrode assembly to remove nonspecific samples from the channel.
[0280] Step 7. The robotic system washes the wells multiple times.
[0281] Step 8. The robotic system transfers primary antibody to the wells.
[0282] Step 9. The robotic system then applies a predetermined voltage to the electrode rails of the electrode assembly to transport primary antibodies into the channels.
[0283] Step 10. The robotic system then washes the wells multiple times.
[0284] Step 11. The robotic system then applies a predetermined voltage to the electrode rails of the electrode assembly to remove unbound primary antibodies from the channels.
[0285] Step. 12 The robotic system then washes the wells multiple times.
[0286] Step 13. Optionally, the robotic system then repeats steps 8-12 as needed. For example, if using a secondary antibody, steps 8-12 may be repeated.
[0287] Step 14. Obtain images of all of the location of the pairs of wells of the chip caddy, and analyzing the image to generate data.
FURTHER EXAMPLES
[0288] Example IB. An automated analyte detection and quantification system with direct sampling capabilities, wherein the automated analyte detection and quantification system comprises a custom-designed automated liquid handling robot having microliter pipetting
capabilities and programmed to deliver, add, aspirate or remove liquids to and from sample wells at defined time intervals or in predetermined conditions, and an assay subunit system comprising a conductive connector assembly, an electrode assembly, a vacuum pump, and a programmable voltage power supply.
[0289] Example 2B. The automated analyte detection and quantification system of Example IB, wherein the automated liquid handling robot comprises a custom-designed and manufactured arm comprising an aspiration manifold connected to a vacuum line and configured for micro tip attachment.
[0290] Example 3B. The automated analyte detection and quantification system of Example 2B, wherein the connector assembly comprises a lid and a printed circuit board (PCB) interface.
[0291] Example 4B. The automated analyte detection and quantification system of Example 3B, wherein the connector assembly is fixed to a plate at the automated liquid handling robot’s base.
[0292] Example 5B. The automated analyte detection and quantification system of Example 4B, wherein the electrode assembly is configured to fit into the connector assembly and to hold consumable assay chips, and wherein the electrode assembly comprises a hinged precision electrode interface.
[0293] Example 6B. The automated analyte detection and quantification system of Example 5B, wherein the hinged precision electrode interface comprises multiple electrode rails.
[0294] Example 7B. The automated analyte detection and quantification system of Example 6B, wherein the connector assembly is configured to transmit electricity to the electrode rails within the electrode assembly.
[0295] Example 8B. The automated analyte detection and quantification system of Example 7B, wherein the electrode assembly comprises a bottom component housing a spring mechanism configured to align a chip caddy within the electrode assembly, and a top lid comprising an insulating electrode frame holding the electrode rails.
[0296] Example 9B. The automated analyte detection and quantification system of Example 8B, wherein the electrode rails are configured to be straight and aligned flat and parallel to the chip caddy.
[0297] Example 10B. The automated analyte detection and quantification system of Example 9B, wherein the electrode assembly is configured to be in open or closed position.
[0298] Example 11B. The automated analyte detection and quantification system of Example 10B, wherein the electrode assembly is removable from the connector assembly.
[0299] Example 12B. The automated analyte detection and quantification system of Example 11B, wherein the electrode assembly is configured to be washed, bleached, disinfected and reused.
[0300] Example 13B. The automated analyte detection and quantification system of Example 12B, wherein the chip caddy contains consumable assay chips.
[0301] Example 14B. The automated analyte detection and quantification system of Example 13B, wherein the consumable assay chips are single use chips.
[0302] Example 15B. The automated analyte detection and quantification system of Example 13B, wherein the consumable assay chips are reusable chips containing wells designed to accept multiple samples and carry out analyte measurement assays on multiple samples simultaneously.
[0303] Example 16B. The automated analyte detection and quantification system of Example 13B, wherein the chip caddy contains 1 or more, 4 or more, 10 or more, 20 or more, 50 or more, or 100 or more consumable assay chips.
[0304] Example 17B. The automated analyte detection and quantification system of Example 16B, wherein each assay chip contains 2 sample wells, 16 sample wells, 64 sample wells, 256 sample wells, 640 sample wells, 1280 sample wells, 3200 sample wells, or 6400 sample wells.
[0305] Example 18B. The automated analyte detection and quantification system of Example 17B, wherein each well has a diameter from about 1 mm to about 5 mm, or from about 1.5 mm to about 3 mm, and wherein two or more wells are interconnected via channels.
[0306] Example 19B. The automated analyte detection and quantification system of Example 5B, wherein the voltage power supply is connected to the electrode interface, and wherein the voltage power supply comprises from 1 to 10 independent outputs.
[0307] Example 20B. The automated analyte detection and quantification system of Example IB, wherein the electrode assembly further comprises an automated imager.
[0308] Example 21B. The automated analyte detection and quantification system of Example 20B, wherein the automated imager is integrated into the system.
[0309] Example 22B. The automated analyte detection and quantification system of Example 20B, wherein the automated imager is separate from the system.
[0310] Example 23B. The automated analyte detection and quantification system of Example 20B, wherein the automatic imager comprises a fluorescence reader.
[0311] Example 24B. The automated analyte detection and quantification system of Example 23B, wherein the software is configured to integrate and connect the liquid handling robot, the vacuum system, the voltage power supply and the automatic imager.
[0312] Example 25B. The automated analyte detection and quantification system of Example 24B, wherein, when the connector assembly and the electrode assembly underneath the connector assembly are in closed position, each electrode in the electrode rails is configured to sit on the edge of each well and to receive electricity through the connector assembly.
[0313] Example 26B. The automated analyte detection and quantification system of Example 25B, wherein each electrode has a thickness between 0.1 mm and 1 mm, or between 0.3 mm and 0.7 mm.
[0314] Example 27B. The automated analyte detection and quantification system of Example 26B, wherein each electrode is a laser-welded platinum electrode comprising an angled top.
[0315] Example 28B. The automated analyte detection and quantification system of Example 27B, wherein the electrode assembly is configured to hold the consumable assay chips in place and maintain electrical conductivity within the wells in the assay chips.
[0316] Example 29B. The automated analyte detection and quantification system of Example 28B, wherein the automated liquid handling robot is configured to deliver or aspirate one or more assay reagents to and from one or more wells in the consumable assay chips at different times or in different sequence.
[0317] Example 30B. The automated analyte detection and quantification system of Example IB, wherein the automated system is configured to detect the presence of one or more analytes in a liquid sample and quantify detected amounts of one or more analytes within a period of time from about 10 minutes to about 4 hours.
[0318] Example 3 IB. The automated analyte detection and quantification system of Example 30, wherein the liquid sample is one or more of a biological sample, a cell suspension, supernatant or lysate, plant extracts, seawater, a microfilm fluid, water samples, or a beverage.
[0319] Example 32B. The automated analyte detection and quantification system of Example 3 IB, wherein the biological sample is blood, serum, urine, or a body fluid from a human or an animal.
[0320] Example 33B. The automated analyte detection and quantification system of Example 32B, wherein the automated system is configured to detect and quantify one or more of a protein, peptide, antibody, nucleic acid, biomarker, hormone, metabolite, carbohydrate and lipid.
[0321] Example 34B. The automated analyte detection and quantification system of Example 33B, wherein detection comprises one or more of an immunoassay, nucleic acid test, multiplex diagnostic test, biomarker measurement or detection, and/or proteomic profiling.
[0322] Example 35B. The automated analyte detection and quantification system of Example IB, wherein the automated system is configured to allow one or more liquid samples and one or more reagents to be separately and at different times introduced into the system.
[0323] Example 36B. The automated analyte detection and quantification system of Example 35B, wherein the liquid sample volume is from about 0.2pl to about IOOOmI.
[0324] Example 37B. The automated analyte detection and quantification system of Example 36B, wherein the automated system is configured to detect and quantify one or more analytes in a period of time from about 10 minutes to about 4 hours.
[0325] Example 38B. The automated analyte detection and quantification system of Example 37B, wherein the automated system is configured to apply directional electric field.
[0326] Example 39B. The automated analyte detection and quantification system of Example 38B, wherein the automated system is configured to allow a liquid handling robot to precisely transfer, dispense into, deliver to or aspirate from different samples one or more reagents at different times or in different cycles, in order to capture and bind target analytes.
[0327] Example 40B. The automated analyte detection and quantification system of Example 39B, wherein capturing and binding target analytes comprise one or more of sandwich antibody detection, enzyme-labeled antigen reaction, fluorometric detection, in situ hybridization, microarray technology, affinity binding, radioactive and colorimetric binding.
[0328] It should be recognized that illustrated embodiments are only examples of the disclosed product and methods and should not be considered a limitation on the scope of the invention. Rather, the scope of the invention is defined by the following claims. We therefore claim as our invention all that comes within the scope and spirit of these claims.
[0329] In the foregoing disclosure, implementations of the disclosure have been described with reference to specific example implementations thereof. It will be evident that various modifications may be made thereto without departing from the broader spirit and scope of implementations of the disclosure as set forth in the following claims. The disclosure and drawings are, accordingly, to be regarded in an illustrative sense rather than a restrictive sense.
Claims
1. An apparatus used to perform an assay, the apparatus comprising: a removable chip caddy comprising: a first frame having one or more assay chips, the assay chips each one or more rows of a plurality of pairs of wells; and an electrode assembly comprising: a second frame, the second frame having a plurality of electrode rails connected to the frame, the electrode rails having a plurality of electrodes.
2. The apparatus of claim 1, wherein in a closed position, the electrodes of an electrode rail are positioned into one of the wells.
3. The apparatus of claim 2, wherein the electrodes when positioned into one of the wells are offset near an edge of the well thereby allowing clearance for the insertion of a pipette tip into the well.
4. The apparatus of any of one of claim 1-3, wherein the second frame includes recessed notches for removably attaching each of the electrode rails.
5. The apparatus of claim 4, wherein each of the electrode rails having a first and second connection end with a tip for securely the electrode rail into the recessed notches.
6. The apparatus of any one of claims 1-5, wherein second frame assembly includes two electrodes rails for each row of the pairs of wells.
7. The apparatus of claim any one of claims 1-6, wherein each of the assay chips are removably attached to the first frame.
8. The apparatus of any one of claims 1 -7 further comprising an assembly lid hingedly attached to a base, wherein the assembly lid when in a closed and locked position secures the second frame in place against the first frame.
9. The apparatus of any one of claims 8, wherein the base includes a post, and the assembly lid includes a locking mechanism for locking the assembly lid into the locked position.
10. The apparatus of any one of claims 1-9, wherein each electrode has a thickness between 0.1 mm and 1 mm, or between 0.3 mm and 0.7 mm.
11. The apparatus of any one of claims 1-10, wherein each well has a diameter from about 1 mm to about 5 mm, or from about 1.5 mm to about 3 mm.
12. The apparatus of any one of claims 1-11, wherein each pair of wells are interconnected via channels.
13. The apparatus of any one of claims 1-12, wherein each well has a volume from about 2.5pL.
14. The apparatus of any one of claims 1-13, wherein the second frame comprises multiple spring mechanisms configured to align the first frame with the second frame.
15. The apparatus of any one of claims 1-14, wherein the electrode rails are configured to be straight and aligned flat and parallel to the rows to sides of the first frame.
16. A method for processing liquid samples, the method comprising: providing one or more assay chips, the assay chips each including one or more rows of a plurality of pairs of wells, wherein the pair of wells are interconnected via channels; placing a fluid into wells of the assay chips using a robotic controlled pipettor, having multiple pipettor tips, such that the fluid contacts an electrode positioned within the well, wherein the fluid includes sample molecules; applying a predetermined voltage via the electrodes to cause the sample molecules to move from a well into the channel; and
aspirating the fluid from the wells using a robotic controlled vacuum aspirator to remove fluid from the wells of the one more assay chips.
17. The method of claim 16, wherein each well has a diameter from about 1 mm to about 5 mm, or from about 1.5 mm to about 3 mm.
18. The method of any one of claims 16-17, washing each of the wells of the assay chips using a robotic controlled pipettor to dispense a fluid for cleaning, and removing the fluid from the wells.
19. The method of any one of claims 16-18, the electrodes are positioned within the wells such that the pipettor tips may be inserted within the wells.
20. The method of any one of claims 16-19, further comprising: placing a first electrode rail over a first row of the pair of wells, and placing a second electrode rail over a second row of the pair of wells, the electrode rails having multiple electrode tips, wherein the respective multiple electrode tips are positioned into a portion of a well within the row; applying a first voltage to the first electrode rail; and applying a second voltage to the second electrode rail.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/794,978 US20230139925A1 (en) | 2020-01-24 | 2021-01-22 | Automated analyte measurement systems and kits for use therewith |
CN202180012000.1A CN115151346A (en) | 2020-01-24 | 2021-01-22 | Automated analyte determination system and kit for use therewith |
JP2022545153A JP2023511602A (en) | 2020-01-24 | 2021-01-22 | Kits for use with automated specimen measurement systems and measurement systems |
EP21744677.2A EP4093548A4 (en) | 2020-01-24 | 2021-01-22 | Automated analyte measurement systems and kits for use therewith |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062965725P | 2020-01-24 | 2020-01-24 | |
US202062965729P | 2020-01-24 | 2020-01-24 | |
US62/965,729 | 2020-01-24 | ||
US62/965,725 | 2020-01-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021151030A1 true WO2021151030A1 (en) | 2021-07-29 |
Family
ID=76992636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/014800 WO2021151030A1 (en) | 2020-01-24 | 2021-01-22 | Automated analyte measurement systems and kits for use therewith |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230139925A1 (en) |
EP (1) | EP4093548A4 (en) |
JP (1) | JP2023511602A (en) |
CN (1) | CN115151346A (en) |
WO (1) | WO2021151030A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023150310A1 (en) * | 2022-02-03 | 2023-08-10 | Correlia Biosystems, Inc. | Automated analyte measurement systems and kits for use therewith |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020190732A1 (en) * | 2000-03-15 | 2002-12-19 | Jing Cheng | Apparatus and method for high throughput electrorotation analysis |
US6562213B1 (en) * | 2000-08-30 | 2003-05-13 | Ethrog Biotechnology Ltd. | Electrophoresis apparatus for simultaneous loading of multiple samples |
US20060216203A1 (en) * | 2005-03-28 | 2006-09-28 | Mds Sciex (Us) A Division Of Mds Pharma Services (Us) Inc. | Multiwell sample plate with integrated impedance electrodes and connection scheme |
US20160327222A1 (en) * | 2013-03-14 | 2016-11-10 | Apex Technologies, Inc. | Suspended Track and Planar Electrode Systems and Methods |
US20170315131A1 (en) * | 2002-12-20 | 2017-11-02 | Acea Biosciences, Inc. | Real time electronic cell sensing systems and applications for cell-based assays |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3525837B2 (en) * | 1999-12-24 | 2004-05-10 | 株式会社日立製作所 | Automatic electrophysiological measuring device and automatic electrophysiological measuring method |
US7270730B2 (en) * | 2000-08-04 | 2007-09-18 | Essen Instruments, Inc. | High-throughput electrophysiological measurement system |
JP4427461B2 (en) * | 2005-01-21 | 2010-03-10 | 株式会社日立ハイテクノロジーズ | Chemical analysis apparatus and analysis device |
DE102009016712A1 (en) * | 2009-04-09 | 2010-10-14 | Bayer Technology Services Gmbh | Disposable microfluidic test cassette for bioassay of analytes |
US20110086778A1 (en) * | 2009-10-13 | 2011-04-14 | Herrmann Mark G | Enhanced microplate configurations |
US8329009B2 (en) * | 2010-04-09 | 2012-12-11 | Molecular Devices, Llc | High throughput screening of ion channels |
US9377439B2 (en) * | 2011-11-25 | 2016-06-28 | Tecan Trading Ag | Disposable cartridge for microfluidics system |
EP2965817B1 (en) * | 2012-10-24 | 2017-09-27 | Genmark Diagnostics Inc. | Integrated multiplex target analysis |
WO2014187488A1 (en) * | 2013-05-23 | 2014-11-27 | Tecan Trading Ag | Digital microfluidics system with swappable pcb`s |
US10078986B2 (en) * | 2015-09-15 | 2018-09-18 | Sharp Life Science (Eu) Limited | Active matrix device and method of driving |
CN109863391B (en) * | 2016-10-05 | 2021-11-05 | 雅培实验室 | Device and method for sample analysis |
US11198129B2 (en) * | 2016-10-05 | 2021-12-14 | Abbott Laboratories | Devices and methods for sample analysis |
CN109709349B (en) * | 2019-03-07 | 2024-02-06 | 南京仁迈生物科技有限公司 | Chemiluminescent immunoassay system |
-
2021
- 2021-01-22 CN CN202180012000.1A patent/CN115151346A/en active Pending
- 2021-01-22 EP EP21744677.2A patent/EP4093548A4/en active Pending
- 2021-01-22 JP JP2022545153A patent/JP2023511602A/en active Pending
- 2021-01-22 US US17/794,978 patent/US20230139925A1/en active Pending
- 2021-01-22 WO PCT/US2021/014800 patent/WO2021151030A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020190732A1 (en) * | 2000-03-15 | 2002-12-19 | Jing Cheng | Apparatus and method for high throughput electrorotation analysis |
US6562213B1 (en) * | 2000-08-30 | 2003-05-13 | Ethrog Biotechnology Ltd. | Electrophoresis apparatus for simultaneous loading of multiple samples |
US20170315131A1 (en) * | 2002-12-20 | 2017-11-02 | Acea Biosciences, Inc. | Real time electronic cell sensing systems and applications for cell-based assays |
US20060216203A1 (en) * | 2005-03-28 | 2006-09-28 | Mds Sciex (Us) A Division Of Mds Pharma Services (Us) Inc. | Multiwell sample plate with integrated impedance electrodes and connection scheme |
US20160327222A1 (en) * | 2013-03-14 | 2016-11-10 | Apex Technologies, Inc. | Suspended Track and Planar Electrode Systems and Methods |
Non-Patent Citations (1)
Title |
---|
See also references of EP4093548A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023150310A1 (en) * | 2022-02-03 | 2023-08-10 | Correlia Biosystems, Inc. | Automated analyte measurement systems and kits for use therewith |
WO2023150302A1 (en) * | 2022-02-03 | 2023-08-10 | Correlia Biosystems, Inc. | System modules for use with fluid sample processing systems |
Also Published As
Publication number | Publication date |
---|---|
US20230139925A1 (en) | 2023-05-04 |
EP4093548A4 (en) | 2024-01-24 |
JP2023511602A (en) | 2023-03-20 |
CN115151346A (en) | 2022-10-04 |
EP4093548A1 (en) | 2022-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Miočević et al. | Quantitative lateral flow assays for salivary biomarker assessment: a review | |
JP2022087140A (en) | Influenza virus real-time detection | |
DE69728158T2 (en) | IMMUNOASSAYS IN CAPILLARY TUBES | |
US20240246076A1 (en) | Non-invasive cancer detection and analysis by single-molecule imaging | |
KR20170024827A (en) | The Quantitative PCR Cartridge with Microchannel-Film Reactor, Nucleic Acid Extraction Module and qPCR Reagents Module, and The Rapid qPCR System Using the Same | |
RU2363951C2 (en) | Micromechanical ways and devices for carrying out of analyses | |
CN107690582A (en) | Apparatus and method for sample analysis | |
US20030050591A1 (en) | Loading system and method for using the same | |
TW200540413A (en) | Biosensors having improved sample application and uses thereof | |
US6495351B2 (en) | Loading system and method for using the same | |
JP2019095457A (en) | Devices, systems, and methods for sample preparation | |
JP2010505108A (en) | Cartridge system | |
KR101900120B1 (en) | Reaction container and method for producing same | |
BRPI0709600A2 (en) | Devices and methods for detecting cells and other analytes | |
US20230139925A1 (en) | Automated analyte measurement systems and kits for use therewith | |
EP2580571A1 (en) | Detection of magnetically labeled biological components | |
CN103443625A (en) | Internal focus reference beads for imaging cytometry | |
WO2017165585A1 (en) | Systems and apparatus for detecting compounds in human biological samples | |
US7828949B2 (en) | Biomolecule detection device, mobile phone for biomolecule detection, and biomolecule detection method | |
Pusic et al. | Modeling neural immune signaling of episodic and chronic migraine using spreading depression in vitro | |
EA028778B1 (en) | Assay device | |
CN114428084A (en) | Micro-fluidic chip and detection system for evaluating biological radiation effect of radioactive particles | |
JP2021151258A (en) | Pre-processing kit for gene analysis, nucleic acid analysis chip, analysis system and chip for living body substance analysis | |
KR101880862B1 (en) | Iron Oxide Nanoparticle Complex And Biosensor Using The Same | |
US20190192698A1 (en) | A method for obtaining indicator signals from a cell |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21744677 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022545153 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021744677 Country of ref document: EP Effective date: 20220824 |